<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--  EDGAR Online I-Metrix Xcelerate Instance Document, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!--  Version: 6.0.12 -->
<!--  Creation date: 2009-08-06T06:59Z -->
<!--  Copyright (c) 2005-2009 EDGAR Online, Inc. All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.us/dei/2008-03-31" xmlns:holx="http://www.hologic.com/20090627" xmlns:us-gaap="http://xbrl.us/us-gaap/2008-03-31" xmlns:us-roles="http://xbrl.us/us-roles/2008-03-31" xmlns:us-types="http://xbrl.us/us-types/2008-03-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="holx-20090627.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE45------0910-Q0003_STD_Inst_20070929_0" unitRef="USD" decimals="-3">100403000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:Assets contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="USD" decimals="-3">8134632000</us-gaap:Assets>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="USD" decimals="-3">0</us-gaap:CommitmentsAndContingencies>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="USDperShareItemType" decimals="2">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="Shares" decimals="-3">750000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="Shares" decimals="-3">256373000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockValue contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="USD" decimals="-3">2564000</us-gaap:CommonStockValue>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="USD" decimals="-3">4945000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="USD" decimals="-3">920838000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:AccountsPayable contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="USD" decimals="-3">59590000</us-gaap:AccountsPayable>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="USD" decimals="-3">4853837000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="USD" decimals="-3">6326000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="USD" decimals="-3">321299000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccruedLiabilities contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="USD" decimals="-3">154746000</us-gaap:AccruedLiabilities>
  <us-gaap:AssetsCurrent contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="USD" decimals="-3">693578000</us-gaap:AssetsCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="USD" decimals="-3">95661000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:ConvertibleDebtNoncurrent contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="USD" decimals="-3">1725000000</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="USD" decimals="-3">78559000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="USD" decimals="-3">10777000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredTaxAssetsNetCurrent contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="USD" decimals="-3">53660000</us-gaap:DeferredTaxAssetsNetCurrent>
  <us-gaap:Goodwill contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="USD" decimals="-3">4450496000</us-gaap:Goodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="USD" decimals="-3">2629651000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:InventoryNet contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="USD" decimals="-3">174667000</us-gaap:InventoryNet>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="USD" decimals="-3">8134632000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="USD" decimals="-3">340875000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LongTermDebtCurrent contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="USD" decimals="-3">38480000</us-gaap:LongTermDebtCurrent>
  <us-gaap:LongTermDebtNoncurrent contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="USD" decimals="-3">437420000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="USD" decimals="-3">76932000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherDeferredCreditsCurrent contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="USD" decimals="-3">9500000</us-gaap:OtherDeferredCreditsCurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="USD" decimals="-3">57453000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="USDperShareItemType" decimals="2">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="Shares" decimals="-3">1623000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="Shares" decimals="-3">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="USD" decimals="-3">0</us-gaap:PreferredStockValue>
  <us-gaap:PrepaidExpenseCurrent contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="USD" decimals="-3">26865000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:PrepaidTaxes contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="USD" decimals="-3">17797000</us-gaap:PrepaidTaxes>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="USD" decimals="-3">283975000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="USD" decimals="-3">3629000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="USD" decimals="-3">-217644000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="USD" decimals="-3">4642269000</us-gaap:StockholdersEquity>
  <us-gaap:TreasuryStockShares contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="Shares" decimals="-3">214000</us-gaap:TreasuryStockShares>
  <us-gaap:TreasuryStockValue contextRef="eol_PE45------0910-Q0003_STD_Inst_20080927_0" unitRef="USD" decimals="-3">1433000</us-gaap:TreasuryStockValue>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE45------0910-Q0003_STD_Inst_20090803_0" unitRef="Shares" decimals="0">256632632</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityPublicFloat contextRef="eol_PE45------0910-Q0003_STD_Inst_20080328_0" unitRef="USD" decimals="0">7082916053</dei:EntityPublicFloat>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE45------0910-Q0003_STD_Inst_20080628_0" unitRef="USD" decimals="-3">119863000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:Assets contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="USD" decimals="-3">5718245000</us-gaap:Assets>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="USD" decimals="-3">0</us-gaap:CommitmentsAndContingencies>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="USDperShareItemType" decimals="2">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="Shares" decimals="-3">750000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="Shares" decimals="-3">256817000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockValue contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="USD" decimals="-3">2568000</us-gaap:CommonStockValue>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="USD" decimals="-3">3431000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="USD" decimals="-3">918603000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:AccountsPayable contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="USD" decimals="-3">49785000</us-gaap:AccountsPayable>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="USD" decimals="-3">4879428000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="USD" decimals="-3">7117000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="USD" decimals="-3">279811000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccruedLiabilities contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="USD" decimals="-3">119757000</us-gaap:AccruedLiabilities>
  <us-gaap:AssetsCurrent contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="USD" decimals="-3">794098000</us-gaap:AssetsCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="USD" decimals="-3">243721000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:ConvertibleDebtNoncurrent contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="USD" decimals="-3">1725000000</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="USD" decimals="-3">92048000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="USD" decimals="-3">11111000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredTaxAssetsNetCurrent contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="USD" decimals="-3">56449000</us-gaap:DeferredTaxAssetsNetCurrent>
  <us-gaap:Goodwill contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="USD" decimals="-3">2100938000</us-gaap:Goodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="USD" decimals="-3">2476659000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:InventoryNet contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="USD" decimals="-3">183401000</us-gaap:InventoryNet>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="USD" decimals="-3">5718245000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="USD" decimals="-3">296445000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LongTermDebtCurrent contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="USD" decimals="-3">25355000</us-gaap:LongTermDebtCurrent>
  <us-gaap:LongTermDebtNoncurrent contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="USD" decimals="-3">256340000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="USD" decimals="-3">68910000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherDeferredCreditsCurrent contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="USD" decimals="-3">9500000</us-gaap:OtherDeferredCreditsCurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="USD" decimals="-3">55573000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="USDperShareItemType" decimals="2">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="Shares" decimals="-3">1623000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="Shares" decimals="-3">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="USD" decimals="-3">0</us-gaap:PreferredStockValue>
  <us-gaap:PrepaidExpenseCurrent contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="USD" decimals="-3">25585000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:PrepaidTaxes contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="USD" decimals="-3">4220000</us-gaap:PrepaidTaxes>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="USD" decimals="-3">277640000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="USD" decimals="-3">911000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="USD" decimals="-3">-2428821000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="USD" decimals="-3">2455173000</us-gaap:StockholdersEquity>
  <us-gaap:TreasuryStockShares contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="Shares" decimals="-3">214000</us-gaap:TreasuryStockShares>
  <us-gaap:TreasuryStockValue contextRef="eol_PE45------0910-Q0003_STD_Inst_20090627_0" unitRef="USD" decimals="-3">1433000</us-gaap:TreasuryStockValue>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE45------0910-Q0003_STD_p3m_20080628_0" unitRef="USDperShareItemType" decimals="2">0.24</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE45------0910-Q0003_STD_p3m_20080628_0" unitRef="USDperShareItemType" decimals="2">0.24</us-gaap:EarningsPerShareDiluted>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="eol_PE45------0910-Q0003_STD_p3m_20080628_0" unitRef="USD" decimals="-3">6267000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE45------0910-Q0003_STD_p3m_20080628_0" unitRef="USD" decimals="-3">121649000</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSoldAmortization contextRef="eol_PE45------0910-Q0003_STD_p3m_20080628_0" unitRef="USD" decimals="-3">24574000</us-gaap:CostOfGoodsSoldAmortization>
  <us-gaap:CostOfServices contextRef="eol_PE45------0910-Q0003_STD_p3m_20080628_0" unitRef="USD" decimals="-3">38506000</us-gaap:CostOfServices>
  <us-gaap:CostsAndExpenses contextRef="eol_PE45------0910-Q0003_STD_p3m_20080628_0" unitRef="USD" decimals="-3" id="fnid_453490_2_17">321871000</us-gaap:CostsAndExpenses>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE45------0910-Q0003_STD_p3m_20080628_0" unitRef="USD" decimals="-3">35043000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GoodwillImpairmentLoss contextRef="eol_PE45------0910-Q0003_STD_p3m_20080628_0" unitRef="USD" decimals="-3">0</us-gaap:GoodwillImpairmentLoss>
  <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="eol_PE45------0910-Q0003_STD_p3m_20080628_0" unitRef="USD" decimals="-3">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE45------0910-Q0003_STD_p3m_20080628_0" unitRef="USD" decimals="-3">94910000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE45------0910-Q0003_STD_p3m_20080628_0" unitRef="USD" decimals="-3">33531000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:InterestExpense contextRef="eol_PE45------0910-Q0003_STD_p3m_20080628_0" unitRef="USD" decimals="-3">14103000</us-gaap:InterestExpense>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE45------0910-Q0003_STD_p3m_20080628_0" unitRef="USD" decimals="-3">604000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:NetIncomeLoss contextRef="eol_PE45------0910-Q0003_STD_p3m_20080628_0" unitRef="USD" decimals="-3">61379000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE45------0910-Q0003_STD_p3m_20080628_0" unitRef="USD" decimals="-3">107621000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE45------0910-Q0003_STD_p3m_20080628_0" unitRef="USD" decimals="-3">788000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE45------0910-Q0003_STD_p3m_20080628_0" unitRef="USD" decimals="-3">20966000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentInProcess contextRef="eol_PE45------0910-Q0003_STD_p3m_20080628_0" unitRef="USD" decimals="-3">0</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:RestructuringCharges contextRef="eol_PE45------0910-Q0003_STD_p3m_20080628_0" unitRef="USD" decimals="-3">6383000</us-gaap:RestructuringCharges>
  <us-gaap:Revenues contextRef="eol_PE45------0910-Q0003_STD_p3m_20080628_0" unitRef="USD" decimals="-3">429492000</us-gaap:Revenues>
  <us-gaap:SalesRevenueGoodsNet contextRef="eol_PE45------0910-Q0003_STD_p3m_20080628_0" unitRef="USD" decimals="-3">384004000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueServicesNet contextRef="eol_PE45------0910-Q0003_STD_p3m_20080628_0" unitRef="USD" decimals="-3">45488000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:SellingAndMarketingExpense contextRef="eol_PE45------0910-Q0003_STD_p3m_20080628_0" unitRef="USD" decimals="-3">68483000</us-gaap:SellingAndMarketingExpense>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE45------0910-Q0003_STD_p3m_20080628_0" unitRef="Shares" decimals="-3">259390000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE45------0910-Q0003_STD_p3m_20080628_0" unitRef="Shares" decimals="-3">255676000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <holx:CostOfGoodsSoldImpairmentOfIntangibleAssets contextRef="eol_PE45------0910-Q0003_STD_p3m_20080628_0" unitRef="USD" decimals="-3">0</holx:CostOfGoodsSoldImpairmentOfIntangibleAssets>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE45------0910-Q0003_STD_p3m_20090627_0" unitRef="USDperShareItemType" decimals="2">0.16</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE45------0910-Q0003_STD_p3m_20090627_0" unitRef="USDperShareItemType" decimals="2">0.16</us-gaap:EarningsPerShareDiluted>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="eol_PE45------0910-Q0003_STD_p3m_20090627_0" unitRef="USD" decimals="-3">13025000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE45------0910-Q0003_STD_p3m_20090627_0" unitRef="USD" decimals="-3">114232000</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSoldAmortization contextRef="eol_PE45------0910-Q0003_STD_p3m_20090627_0" unitRef="USD" decimals="-3">40773000</us-gaap:CostOfGoodsSoldAmortization>
  <us-gaap:CostOfServices contextRef="eol_PE45------0910-Q0003_STD_p3m_20090627_0" unitRef="USD" decimals="-3">36970000</us-gaap:CostOfServices>
  <us-gaap:CostsAndExpenses contextRef="eol_PE45------0910-Q0003_STD_p3m_20090627_0" unitRef="USD" decimals="-3" id="fnid_453490_1_17">324374000</us-gaap:CostsAndExpenses>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE45------0910-Q0003_STD_p3m_20090627_0" unitRef="USD" decimals="-3">37039000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GoodwillImpairmentLoss contextRef="eol_PE45------0910-Q0003_STD_p3m_20090627_0" unitRef="USD" decimals="-3">0</us-gaap:GoodwillImpairmentLoss>
  <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="eol_PE45------0910-Q0003_STD_p3m_20090627_0" unitRef="USD" decimals="-3">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE45------0910-Q0003_STD_p3m_20090627_0" unitRef="USD" decimals="-3">60670000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE45------0910-Q0003_STD_p3m_20090627_0" unitRef="USD" decimals="-3">19670000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:InterestExpense contextRef="eol_PE45------0910-Q0003_STD_p3m_20090627_0" unitRef="USD" decimals="-3">17552000</us-gaap:InterestExpense>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE45------0910-Q0003_STD_p3m_20090627_0" unitRef="USD" decimals="-3">206000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:NetIncomeLoss contextRef="eol_PE45------0910-Q0003_STD_p3m_20090627_0" unitRef="USD" decimals="-3">41000000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE45------0910-Q0003_STD_p3m_20090627_0" unitRef="USD" decimals="-3">78746000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE45------0910-Q0003_STD_p3m_20090627_0" unitRef="USD" decimals="-3">-730000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE45------0910-Q0003_STD_p3m_20090627_0" unitRef="USD" decimals="-3">23407000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentInProcess contextRef="eol_PE45------0910-Q0003_STD_p3m_20090627_0" unitRef="USD" decimals="-3">0</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:RestructuringCharges contextRef="eol_PE45------0910-Q0003_STD_p3m_20090627_0" unitRef="USD" decimals="-3">0</us-gaap:RestructuringCharges>
  <us-gaap:Revenues contextRef="eol_PE45------0910-Q0003_STD_p3m_20090627_0" unitRef="USD" decimals="-3">403120000</us-gaap:Revenues>
  <us-gaap:SalesRevenueGoodsNet contextRef="eol_PE45------0910-Q0003_STD_p3m_20090627_0" unitRef="USD" decimals="-3">349414000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueServicesNet contextRef="eol_PE45------0910-Q0003_STD_p3m_20090627_0" unitRef="USD" decimals="-3">53706000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:SellingAndMarketingExpense contextRef="eol_PE45------0910-Q0003_STD_p3m_20090627_0" unitRef="USD" decimals="-3">58928000</us-gaap:SellingAndMarketingExpense>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE45------0910-Q0003_STD_p3m_20090627_0" unitRef="Shares" decimals="-3">258908000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE45------0910-Q0003_STD_p3m_20090627_0" unitRef="Shares" decimals="-3">256556000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <holx:CostOfGoodsSoldImpairmentOfIntangibleAssets contextRef="eol_PE45------0910-Q0003_STD_p3m_20090627_0" unitRef="USD" decimals="-3">0</holx:CostOfGoodsSoldImpairmentOfIntangibleAssets>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">19460000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USDperShareItemType" decimals="2">-0.99</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USDperShareItemType" decimals="2">-0.99</us-gaap:EarningsPerShareDiluted>
  <us-gaap:AmortizationOfFinancingCosts contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">16035000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">18685000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AdjustmentForAmortization contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">88347000</us-gaap:AdjustmentForAmortization>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">397030000</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSoldAmortization contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">69649000</us-gaap:CostOfGoodsSoldAmortization>
  <us-gaap:CostOfServices contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">113071000</us-gaap:CostOfServices>
  <us-gaap:CostsAndExpenses contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3" id="fnid_453490_4_17">1341037000</us-gaap:CostsAndExpenses>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">-20797000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:Depreciation contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">38631000</us-gaap:Depreciation>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">-1705000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">53688000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">53688000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">-1715000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">109111000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GoodwillImpairmentLoss contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">0</us-gaap:GoodwillImpairmentLoss>
  <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">2900000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
  <us-gaap:ImpairmentOfInvestments contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">0</us-gaap:ImpairmentOfInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">-169809000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">71435000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">-9135000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">43076000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">342000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">22037000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">38015000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">11493000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">-2296000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:InterestExpense contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">65102000</us-gaap:InterestExpense>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">3729000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">1855512000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">-2073408000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">239061000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">-241244000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">-109051000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherAdjustmentsForNoncashItemsIncludedInIncomeLossFromContinuingOperations contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">538000</us-gaap:OtherAdjustmentsForNoncashItemsIncludedInIncomeLossFromContinuingOperations>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">615000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherPaymentsToAcquireBusinesses contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">956000</us-gaap:OtherPaymentsToAcquireBusinesses>
  <us-gaap:PaymentsOfFinancingCosts contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">0</us-gaap:PaymentsOfFinancingCosts>
  <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">2027017000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
  <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">0</us-gaap:PaymentsToAcquireIntangibleAssets>
  <us-gaap:PaymentsToAcquireLifeInsurancePolicies contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">3322000</us-gaap:PaymentsToAcquireLifeInsurancePolicies>
  <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">263000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:PaymentsToAcquireOtherInvestments contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">0</us-gaap:PaymentsToAcquireOtherInvestments>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">42270000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">1688974000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromLinesOfCredit contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">2335679000</us-gaap:ProceedsFromLinesOfCredit>
  <us-gaap:ProceedsFromNotesPayable contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">2227000</us-gaap:ProceedsFromNotesPayable>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">2638000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">936000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
  <us-gaap:ProceedsFromSaleOfIntangibleAssets contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">3000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
  <us-gaap:RepaymentsOfAssumedDebt contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">40574000</us-gaap:RepaymentsOfAssumedDebt>
  <us-gaap:RepaymentsOfLinesOfCredit contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">2350000000</us-gaap:RepaymentsOfLinesOfCredit>
  <us-gaap:RepaymentsOfNotesPayable contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">2354000</us-gaap:RepaymentsOfNotesPayable>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">60477000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentInProcess contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">370000000</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:RestructuringCharges contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">6383000</us-gaap:RestructuringCharges>
  <us-gaap:Revenues contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">1231986000</us-gaap:Revenues>
  <us-gaap:SalesRevenueGoodsNet contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">1108430000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueServicesNet contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">123556000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:SellingAndMarketingExpense contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">193731000</us-gaap:SellingAndMarketingExpense>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">19488000</us-gaap:ShareBasedCompensation>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="Shares" decimals="-3">242604000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="Shares" decimals="-3">242604000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <holx:PaymentForTaxWithholdingRelatedToVestedAndReleasedRestrictedStockUnits contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">851000</holx:PaymentForTaxWithholdingRelatedToVestedAndReleasedRestrictedStockUnits>
  <holx:CostOfGoodsSoldImpairmentOfIntangibleAssets contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">0</holx:CostOfGoodsSoldImpairmentOfIntangibleAssets>
  <holx:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">168723000</holx:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
  <holx:ImpairmentOfIntangibleAssetsFinitelived contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">2900000</holx:ImpairmentOfIntangibleAssetsFinitelived>
  <holx:FairValueWriteUpOfAcquiredInventory contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">42325000</holx:FairValueWriteUpOfAcquiredInventory>
  <holx:IncreaseDecreaseInPrepaidIncomeTaxes contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">-54151000</holx:IncreaseDecreaseInPrepaidIncomeTaxes>
  <holx:PaymentsToManufactureEquipmentUnderCustomerUsageAgreements contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">17950000</holx:PaymentsToManufactureEquipmentUnderCustomerUsageAgreements>
  <holx:ProceedsFromContingentSaleOfAssets contextRef="eol_PE45------0910-Q0003_STD_p9m_20080628_0" unitRef="USD" decimals="-3">9500000</holx:ProceedsFromContingentSaleOfAssets>
  <dei:DocumentType contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0">10-Q</dei:DocumentType>
  <dei:AmendmentFlag contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0">false</dei:AmendmentFlag>
  <dei:AmendmentDescription contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0">N.A.</dei:AmendmentDescription>
  <dei:DocumentPeriodEndDate contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0">2009-06-27</dei:DocumentPeriodEndDate>
  <dei:EntityRegistrantName contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0">HOLOGIC INC</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0">0000859737</dei:EntityCentralIndexKey>
  <dei:TradingSymbol contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0">HOLX</dei:TradingSymbol>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0">--09-26</dei:CurrentFiscalYearEndDate>
  <dei:EntityWellKnownSeasonedIssuer contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0">Yes</dei:EntityWellKnownSeasonedIssuer>
  <dei:EntityVoluntaryFilers contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0">No</dei:EntityVoluntaryFilers>
  <dei:EntityCurrentReportingStatus contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0">Large Accelerated Filer</dei:EntityFilerCategory>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">148060000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font size="2"
face="Times New Roman"&gt;&lt;b&gt;(3) Disclosure of Fair Value of Financial
Instruments&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The Company&amp;#8217;s financial
instruments mainly consist of cash and cash equivalents, accounts
receivable, cost-method investments, accounts payable and debt
obligations. The carrying amounts of the Company&amp;#8217;s cash
equivalents, accounts receivable and accounts payable approximate
fair value due to the short-term nature of these instruments. The
Company believes the carrying amounts of its cost-method
investments approximate fair value and has not performed an
in-depth analysis of the fair values as it is not practical to do
so. Amounts outstanding under the Company&amp;#8217;s Amended Credit
Agreement (See Note 6) are subject to variable rates of interest
based on current market rates. As such, the Company believes the
carrying amount of this obligation approximates its fair
value.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font size=
"1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The Company&amp;#8217;s AEG
subsidiary also has several notes payable outstanding (See Note 6).
These notes payable are denominated in either the Euro or US dollar
and have variable rates of interest. As of June&amp;#160;27, 2009 and
September&amp;#160;27, 2008, amounts outstanding under these notes
payable approximate their fair value based on comparable market
terms and conditions.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The Company has $1,725,000 of
Convertible Notes outstanding (See Note 6) as of June&amp;#160;27, 2009
and September&amp;#160;27, 2008. The fair value of these Convertible
Notes was approximately $1,231,000 and $1,300,000 as of
June&amp;#160;27, 2009 and September&amp;#160;27, 2008, respectively, based
on the trading prices at those dates.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;

</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font size="2"
face="Times New Roman"&gt;&lt;b&gt;(4) Business Combinations&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;&lt;i&gt;&lt;u&gt;(a) Third Wave
Technologies, Inc.&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;On July&amp;#160;24,
2008&amp;#160;the Company completed its acquisition of Third Wave
Technologies, Inc. (&amp;#8220;Third Wave&amp;#8221;) pursuant to a
definitive agreement dated June&amp;#160;8, 2008. The Company concluded
that the acquisition of Third Wave did not represent a material
business combination and therefore no pro-forma financial
information has been provided herein. Subsequent to the acquisition
date, the Company&amp;#8217;s results of operations include the results
of Third Wave, which is being reported as a component of the
Company&amp;#8217;s Diagnostics reporting segment.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;Third Wave, located in
Madison, Wisconsin, develops and markets molecular diagnostic
reagents for a wide variety of DNA and RNA analysis applications
based on its proprietary Invader chemistry. Third Wave&amp;#8217;s
current clinical diagnostic offerings consist of products for
conditions such as Cystic Fibrosis, cardiovascular risk and other
diseases. Third Wave recently received approval for two human
papillomavirus (&amp;#8220;HPV&amp;#8221;) tests from the U.S. Food and
Drug Administration (&amp;#8220;FDA&amp;#8221;).&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The Company paid $11.25 per
share of Third Wave, for an aggregate purchase price of
approximately $591,100 (subject to adjustment) consisting of
approximately $575,400 in cash in exchange for stock and warrants;
approximately 668 of fully vested stock options granted to Third
Wave employees in exchange for their vested Third Wave stock
options, with an estimated fair value of approximately $8,100; and
approximately $7,600 for acquisition related fees and expenses.
There are no potential contingent consideration arrangements
payable to the former shareholders in connection with this
transaction. Additionally, the Company granted approximately 315
unvested stock options in exchange for unvested Third Wave stock
options, with an estimated fair value of approximately $5,100,
which is being recognized as compensation expense over the vesting
period.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The Company determined the
fair value of the options issued in connection with the acquisition
in accordance with EITF Issue No.&amp;#160;99-12, &lt;i&gt;Determination of
the Measurement Date for the Market Price of Acquirer Securities
Issued in a Purchase Business Combination&lt;/i&gt; (&amp;#8220;EITF
99-12&amp;#8221;). The Company determined the measurement date to be
July&amp;#160;24, 2008, the date the transaction was completed, as the
number of shares to be issued according to the exchange ratio was
not fixed until this date. The Company valued the securities based
on the average market price for two days before the measurement
date and the measurement date itself. The weighted average stock
price was determined to be approximately $23.54.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The preliminary purchase
price is as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#160;&lt;/p&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" width="84%"
align="center"&gt;&lt;!-- 5 First_Row * DO NOT REMOVE OR EDIT --&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="89%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Cash portion of consideration&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;575,400&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Fair value of vested options exchanged&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;8,100&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Direct acquisition costs&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;7,600&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Total estimated purchase price&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;591,100&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- 6 Last_Row * DO NOT REMOVE OR EDIT --&gt;&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The fair value of vested
Hologic common stock options exchanged for vested Third Wave
options was included in the purchase price as such options were
fully vested. The Company estimated the fair value of these stock
options using the Binomial Option Pricing Model. The Company
estimated the fair value of the stock options assuming no expected
dividends and the following weighted-average
assumptions:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#160;&lt;/p&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" width="84%"
align="center"&gt;&lt;!-- 5 First_Row * DO NOT REMOVE OR EDIT --&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="87%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Expected life&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;1.48&amp;#160;years&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;42.16&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;2.33&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Fair value per share determined in accordance
with EITF 99-12&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;23.54&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- 6 Last_Row * DO NOT REMOVE OR EDIT --&gt;&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The allocation of the
purchase price is based upon estimates of the fair value of assets
acquired and liabilities assumed as of July&amp;#160;24, 2008. At
June&amp;#160;27, 2009, the components and allocation of the purchase
price consist of the following approximate amounts:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#160;&lt;/p&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" width="84%"
align="center"&gt;&lt;!-- 5 First_Row * DO NOT REMOVE OR EDIT --&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="89%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Net tangible assets acquired as of July&amp;#160;24,
2008&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;87,300&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Increase in inventory to fair value&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;5,100&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Increase in property and equipment to fair
value&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;800&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;In-process research and development&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;195,200&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Developed technology and know-how&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;92,300&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Deferred income tax liability&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;(26,300&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Goodwill&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;236,700&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Estimated Purchase Price&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;591,100&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- 6 Last_Row * DO NOT REMOVE OR EDIT --&gt;&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font size=
"1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The preliminary purchase
price allocation resulted in goodwill of approximately $241,800 as
of July&amp;#160;24, 2008, the date of the acquisition. During the nine
months ended June&amp;#160;27, 2009, the Company decreased goodwill in
the amount of approximately $5,100, primarily related to a $2,000
increase in the estimated net operating loss acquired and a $3,000
increase in the preliminary estimate of other tax attributes
acquired.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;Subsequent to the close of
the Third Wave acquisition through June&amp;#160;27, 2009, stock
options, originally issued by Third Wave and converted into options
to purchase Hologic common stock, were exercised. The Company
recorded the estimated tax benefit of approximately $121 and $368
related to the exercise of these options as a reduction to goodwill
during fiscal 2009 and fiscal 2008, respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font size="2"
face="Times New Roman"&gt;&lt;i&gt;Identifiable Intangible
Assets&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;As part of the preliminary
purchase price allocation, all intangible assets that were a part
of the acquisition were identified and valued. It was determined
that only developed technology had separately identifiable values.
The fair value of the developed technology intangible assets was
determined through the application of the income approach.
Developed technology represents currently marketable purchased
products that the Company continues to sell as well as utilize to
enhance and incorporate into the Company&amp;#8217;s existing products.
See Note 17 for discussion of estimated useful lives and
amortization method.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font size="2"
face="Times New Roman"&gt;&lt;i&gt;Acquired In-Process Research and
Development&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;As part of the preliminary
purchase price allocation for Third Wave, approximately $195,200 of
the purchase price was allocated to acquired in-process research
and development projects. The amount allocated to acquired
in-process research and development represented the estimated fair
value, based on risk-adjusted cash flows, of in-process projects
utilizing a discount rate of 20% that have not yet reached
technological feasibility and have no alternative future uses as of
the date of the acquisition. The primary basis for determining the
technological feasibility of these projects was obtaining
regulatory approval to market the underlying products. The fair
value attributable to these in-process projects was expensed at the
time of the acquisition.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The most significant acquired
in-process technology related to the Cervista High HPV Risk
(&amp;#8220;HR&amp;#8221;), for which the Company estimated a value of
approximately $151,200. At the time of, and subsequent to the
acquisition, the Company sold HPV reagents that detect certain high
risk HPV types as Analyte Specific Reagents (&amp;#8220;ASRs&amp;#8221;).
In 2006, Third Wave began clinical trials for PMA submissions to
the FDA for Cervista HR and submitted the PMAs in April 2008.
During March 2009, the FDA approved the Company&amp;#8217;s PMAs for
both the Cervista HPV HR and Cervista HPV 16/18 tests. Subsequent
to receiving FDA approval, management expects to transition to only
selling HPV In Vitro Diagnostics (&amp;#8220;IVDs&amp;#8221;) in the
future. The HPV in-process research and development related only to
the HPV IVDs, and the HPV ASRs were valued as developed
technology.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The estimated cost to
complete Third Wave&amp;#8217;s other remaining in-process research and
development projects in the aggregate as of June&amp;#160;27, 2009 was
approximately $4,800.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The net deferred income tax
liability relates to the tax effect of acquired identifiable
intangible assets and fair value adjustments to acquired inventory
and property and equipment, as such amounts are not deductible for
tax purposes.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;&lt;u&gt;(b) Cytyc
Corporation&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;On October&amp;#160;22, 2007, the
Company completed its merger with Cytyc Corporation
(&amp;#8220;Cytyc&amp;#8221;) pursuant to the Agreement and Plan of Merger
(&amp;#8220;Merger Agreement&amp;#8221;) entered into on May&amp;#160;20, 2007.
Cytyc, headquartered in Marlborough, Massachusetts, is a
diversified diagnostic and medical device company that designs,
develops, manufactures, and markets innovative and clinically
effective diagnostics and surgical products. Cytyc products cover a
range of cancer and women&amp;#8217;s health applications, including
cervical cancer screening, prenatal diagnostics, treatment of
excessive menstrual bleeding and radiation treatment of early-stage
breast cancer.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;Upon the close of the merger,
Cytyc shareholders received an aggregate of 132,038 shares of
Hologic common stock and approximately $2,094,800 in cash. In
connection with the close of the merger, the Company entered into a
credit agreement relating to a senior secured credit facility (the
&amp;#8220;Credit Agreement&amp;#8221;) with Goldman Sachs Credit Partners
L.P. and certain other lenders, in which the lenders committed to
provide, in the aggregate, senior secured financing of up to
approximately $2,550,000 to pay for the cash portion of the merger
consideration, the repayment of existing debt of Cytyc, expenses
related to the merger and working capital requirements following
the completion of the merger. As of the closing of the merger, the
Company borrowed $2,350,000 under this Credit Agreement.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font size=
"1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The aggregate purchase price
of approximately $6,156,900 included $2,094,800 in cash; 132,038
shares of Hologic common stock at an estimated fair value of
$3,671,500; approximately 16,465 of fully vested stock options
granted to Cytyc employees in exchange for their vested Cytyc stock
options, with an estimated fair value of approximately $241,400;
the fair value of Cytyc&amp;#8217;s outstanding convertible notes
assumed in the merger of approximately $125,000; and approximately
$24,200 of direct acquisition costs. There were no potential
contingent consideration arrangements payable to the former Cytyc
shareholders in connection with this transaction.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The Company measured the fair
value of the 132,038 shares of the Company common stock issued as
consideration in connection with the merger under
EITF&amp;#160;99-12&lt;i&gt;.&lt;/i&gt; The Company determined the measurement date
to be May&amp;#160;20, 2007, the date the transaction was announced, as
the number of shares to be issued according to the exchange ratio
was fixed without subsequent revision. The Company valued the
securities based on the average market price a few days before and
after the measurement date. The weighted average stock price was
determined to be approximately $27.81.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font size=
"1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font size="2" face=
"Times New Roman"&gt;(i) Purchase price&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The purchase price was as
follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#160;&lt;/p&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" width="84%"
align="center"&gt;&lt;!-- 5 First_Row * DO NOT REMOVE OR EDIT --&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="87%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Cash portion of consideration&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;2,094,800&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Fair value of securities issued&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;3,671,500&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Fair value of vested options exchanged&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;241,400&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Fair value of Cytyc&amp;#8217;s outstanding
convertible notes&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;125,000&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Direct acquisition costs&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;24,200&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Total estimated purchase price&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;6,156,900&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- 6 Last_Row * DO NOT REMOVE OR EDIT --&gt;&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The fair value of vested
Hologic common stock options exchanged for vested Cytyc options was
included in the purchase price as such options were fully vested.
The Company estimated the fair value of these stock options using
the Binomial Option Pricing Model. The Company estimated the fair
value of the stock options assuming no expected dividends and the
following weighted-average assumptions:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#160;&lt;/p&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" width="84%"
align="center"&gt;&lt;!-- 5 First_Row * DO NOT REMOVE OR EDIT --&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="87%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Expected life&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;2.50&amp;#160;years&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;35.10&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;4.82&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Fair value per share determined in accordance
with EITF 99-12&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;27.81&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- 6 Last_Row * DO NOT REMOVE OR EDIT --&gt;&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font size="2"
face="Times New Roman"&gt;(ii) Purchase Price Allocation&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The allocation of the
purchase price was based upon estimates of the fair value of assets
acquired and liabilities assumed as of October&amp;#160;22, 2007. As a
result of the merger, the Company assumed Cytyc&amp;#8217;s obligation
to the former stockholders of Adiana, Inc. to make contingent
earn-out payments based on the achievement of milestones. The
Company considered the provisions of EITF Issue No.&amp;#160;95-8,
&lt;i&gt;Accounting for Contingent Consideration Paid to the Shareholders
of an Acquired Enterprise in a Purchase Business Combination&lt;/i&gt;,
and concluded that this contingent consideration will represent
additional purchase price. As a result, goodwill will be increased
by the amount of the additional consideration, if any, when it
becomes due and payable. As of June&amp;#160;27, 2009, the Company had
not recorded any amounts for the potential earn-outs. The Company
received FDA approval on July&amp;#160;6, 2009. See Note 7 for
additional discussion. The Company had formulated and undertaken a
plan to restructure certain of Cytyc&amp;#8217;s activities. The
Company recorded a liability of approximately $2,800 in accordance
with EITF Issue No.&amp;#160;95-3, &lt;i&gt;Recognition of Liabilities in
Connection with a Purchase Business Combination&lt;/i&gt; (&amp;#8220;EITF
95-3&amp;#8221;), primarily related to the termination of certain
employees, minimum inventory purchase commitments and other
contractual obligations for which the related business activities
had been discontinued.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#160;&lt;/p&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" width="84%"
align="center"&gt;&lt;!-- 5 First_Row * DO NOT REMOVE OR EDIT --&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="87%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Book value of net assets acquired as of
October&amp;#160;22, 2007&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;1,158,600&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Less: write-off of existing deferred financing
costs, goodwill and intangible assets, including related deferred
taxes&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;(787,900&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Adjusted book value of assets acquired&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;370,700&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Remaining allocation:&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Increase inventory to fair value&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;42,300&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Increase property and equipment to fair
value&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;5,100&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Increase in liabilities recorded in accordance
with EITF 95-3&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;(2,800&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Decrease deferred revenue to fair
value&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;400&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Identifiable intangible assets at fair
value&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;2,486,600&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Acquired in-process research and
development&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;370,000&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Deferred taxes&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;(943,400&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Goodwill&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;3,828,000&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Total purchase price&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;6,156,900&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- 6 Last_Row * DO NOT REMOVE OR EDIT --&gt;&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font size=
"1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font size="2" face=
"Times New Roman"&gt;(iii) Valuation of Intangible Assets and
Goodwill&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The purchase price for the
merger with Cytyc was allocated to assets acquired and liabilities
assumed based on management&amp;#8217;s estimate of their fair values.
Management allocated the purchase price in excess of net tangible
assets acquired to identifiable intangible assets and in-process
research and development based upon a detailed valuation that
relies on information and assumptions further described below. Any
excess purchase price over the fair value of the net tangible and
intangible assets acquired and liabilities assumed was allocated to
goodwill.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font size="2"
face="Times New Roman"&gt;&lt;i&gt;Identifiable Intangible
Assets&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;As part of the purchase price
allocation, the Company determined that Cytyc&amp;#8217;s identifiable
intangible assets included existing technology, customer
relationships and trade names. Cytyc&amp;#8217;s existing technology
related to patents, patent applications and know-how with respect
to the technologies embedded in its currently marketed products. In
determining the allocation of the purchase price to existing
technology, consideration was only given to patents and patent
applications that related to products that had been approved by the
FDA. Cytyc&amp;#8217;s customer relationship assets related to
relationships that Cytyc&amp;#8217;s sales force had developed with
obstetricians/gynecologists and gynecological surgeons, breast
surgeons, radiation oncologists, clinical laboratories and other
physicians. The trade names related to both the Cytyc name as well
as key product names.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The Company used the income
approach to value the existing technology and marketing based
intangibles. This approach calculates fair value by discounting the
after-tax cash flows back to a present value. The baseline data for
this analysis was the cash flow estimates used to price the
transaction. Cash flows were forecasted for each intangible asset,
then discounted based on an appropriate discount rate. The discount
rates applied, which ranged between 10.5% and 13.5%, were
benchmarked with reference to the implied rate of return from the
transaction model as well as Cytyc&amp;#8217;s weighted average cost of
capital based on the capital asset pricing model.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;In estimating the useful life
of the acquired assets, the Company considered paragraph 11 of SFAS
No.&amp;#160;142, &lt;i&gt;Goodwill and Other Intangible Assets,&lt;/i&gt; which
lists the pertinent factors to be considered when estimating the
useful life of an intangible asset. These factors included a review
of the expected use by the combined company of the assets acquired,
the expected useful life of another asset (or group of assets)
related to the acquired assets, legal, regulatory or other
contractual provisions that may limit the useful life of an
acquired asset or may enable the extension of the useful life of an
acquired asset without substantial cost, the effects of
obsolescence, demand, competition and other economic factors, and
the level of maintenance expenditures required to obtain the
expected future cash flows from the asset. See Note 17 for
discussion of estimated useful lives and amortization
method.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font size="2"
face="Times New Roman"&gt;&lt;i&gt;Acquired In-Process Research and
Development&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;As part of the purchase price
allocation for Cytyc, approximately $370,000 of the purchase price
was allocated to acquired in-process research and development
projects. The amount allocated to acquired in-process research and
development represented the estimated fair value, based on
risk-adjusted cash flows, of in-process projects that had not yet
reached technological feasibility and had no alternative future
uses as of the date of the merger. The primary basis for
determining the technological feasibility of these projects was
obtaining regulatory approval to market the underlying products.
The fair value attributable to these in-process projects was
expensed at the time of the merger.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The fair value assigned to
acquired in-process research and development was determined by
estimating the costs to develop the acquired technology into
commercially viable products, estimating the resulting net cash
flows from the projects, and discounting the net cash flows to
their present value. The revenue projections used to value the
acquired in-process research and development were based on
estimates of relevant market sizes and growth factors, expected
trends in technology, and the nature and expected timing of new
product introductions by the Company and its competitors. The
resulting net cash flows from such projects were based on
management&amp;#8217;s estimates of cost of sales, operating expenses,
and income taxes from such projects.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The rates utilized to
discount the net cash flows to their present value of 12.5% to
13.5% were based on estimated cost of capital calculations and the
implied rate of return from the transaction model plus a risk
premium. Due to the nature of the forecasts and the risks
associated with the developmental projects, appropriate
risk-adjusted discount rates were used for the in-process research
and development projects. The discount rates were based on the
stage of completion and uncertainties surrounding the successful
development of the purchased in-process technology
projects.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The acquired in-process
research and development of Cytyc related to the following research
and development projects: Adiana Complete TransCervical
Sterilization System, which the Company subsequently renamed Adiana
Permanent Contraception, and expanded labeling of the NovaSure
System, Gestiva, the ThinPrep Imaging System, the ThinPrep
Processor and the Helica Thermal Coagulator System
(&amp;#8220;Helica&amp;#8221;).&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font size=
"1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The most significant acquired
in-process technology related to the Adiana Permanent Contraception
system for which the Company estimated a value of approximately
$220,000. The Adiana Permanent Contraception system includes an
incisionless trans-cervical permanent sterilization device intended
to be performed as an office-based procedure. The system consists
of three different parts: a disposable applicator, an implantable
polymer matrix and a radio frequency controller. The Company
completed this in-process research and development project during
the three months ended June&amp;#160;27, 2009 and received FDA approval
on July&amp;#160;6, 2009.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;Cytyc&amp;#8217;s other
in-process research and development projects were at different
stages of development, ranging from the early stages of development
to Phase IIb prototype building, ongoing clinical trials and
submission to the FDA of PMA and drug applications. FDA approval or
clearance had not been granted for any of the products classified
as in-process research and development, nor had Cytyc received any
foreign approvals or clearances for any of these products. All
products classified as in-process research and development required
various levels of in-house and external testing, clinical trials
and approvals from the FDA before these future products could be
marketed. The estimated cash requirements in the aggregate to
complete the development of these remaining products as of
June&amp;#160;27, 2009 are expected to be approximately $3,900. Certain
of these projects that have been discontinued or delayed are not
included in this estimate as their cost to complete and timing of
completion are unknown at this time. Certain of the projects
included in this estimated cash requirement have been delayed to
fiscal 2010 and the estimated costs for these projects have been
increased accordingly.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The successful development of
new products and product enhancements is subject to numerous risks
and uncertainties, both known and unknown, including, unanticipated
delays, access to capital, budget overruns, technical problems and
other difficulties that could result in the abandonment or
substantial change in the design, development and commercialization
of these new products and enhancements including, for example,
changes requested by the FDA in connection with PMA applications
for products or 510(k) notification. Given the uncertainties
inherent with product development and introduction, there can be no
assurance that any of the Company&amp;#8217;s product development
efforts will be successful on a timely basis or within budget, if
at all. The failure of the Company to develop new products and
product enhancements on a timely basis or within budget could harm
the Company&amp;#8217;s results of operations and financial
condition.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font size="2"
face="Times New Roman"&gt;&lt;i&gt;Goodwill&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The preliminary purchase
price allocation resulted in goodwill of approximately $3,844,100
as of October&amp;#160;22, 2007, the date of the merger. During the
nine months ended June&amp;#160;27, 2009, the Company reduced goodwill
related to the Cytyc merger by approximately $2,100 primarily due
to a decrease in the valuation allowance related to certain tax
assets acquired where the Company has determined that it is more
likely than not that these assets will be realized. The Company had
previously reduced this goodwill in the amount of approximately
$14,200 from the date of acquisition through September&amp;#160;27,
2008. The reduction was primarily related to a $16,800 increase in
the preliminary valuation of assets acquired (primarily related to
deferred tax assets acquired), an $1,845 increase in the
preliminary valuation of certain tangible assets and a $1,700
increase in the preliminary valuation of certain intangible assets
which were partially offset by a $5,900 increase in the preliminary
estimate of liabilities assumed (primarily related to current tax
liabilities) and a $200 increase in the preliminary estimate of
acquisition costs and expenses.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The factors contributing to
the recognition of this amount of goodwill were based upon several
strategic and synergistic benefits that were expected to be
realized from the combination. These benefits included the
expectation that the Company&amp;#8217;s complementary products and
technologies would create a leading women&amp;#8217;s healthcare
company with an enhanced presence in hospitals, private practices
and healthcare organizations. The Company also expected to realize
substantial synergies through the use of Cytyc&amp;#8217;s OB/GYN and
breast surgeon sales channel to cross-sell the Company&amp;#8217;s
existing and future products. The merger provided the Company
broader channel coverage within the U.S. and expanded geographic
reach internationally, as well as increased scale and scope for
further expanding operations through product development and
complementary strategic transactions.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;Subsequent to the close of
the Cytyc merger through December&amp;#160;27, 2008, vested stock
options, originally issued by Cytyc and converted into options to
purchase Hologic common stock, were exercised. The Company recorded
the estimated tax benefit of approximately $49,300 related to the
exercise of these options as a reduction to goodwill during fiscal
2008 and $64 during fiscal 2009.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;As a result of the
Company&amp;#8217;s interim impairment analysis of goodwill as of
December&amp;#160;27, 2008, the Company recorded an impairment charge
of $2,340,023. The goodwill related to this acquisition has been
reduced from $3,778,700 at December&amp;#160;27, 2008 to approximately
$1,438,500 as of June&amp;#160;27, 2009. See Note 17 for additional
information pertaining to the interim impairment analysis of the
Company&amp;#8217;s goodwill.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font size="2"
face="Times New Roman"&gt;&lt;i&gt;Supplemental Pro-forma
Information&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The following unaudited
pro-forma information presents the consolidated results of
operations of the Company and Cytyc as if the transaction had
occurred at the beginning of the period presented, with pro-forma
adjustments to give effect to amortization of intangible assets, an
increase in interest expense on acquisition financing, subsequent
refinancing and certain other adjustments together with related tax
effects:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#160;&lt;/p&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" width="84%"
align="center"&gt;&lt;!-- 5 First_Row * DO NOT REMOVE OR EDIT --&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="82%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;
&lt;p style="BORDER-BOTTOM: #000000 1px solid; WIDTH: 202pt"&gt;
&lt;font size="1" face="Times New Roman"&gt;&lt;b&gt;(approximate amounts in
thousands, except per share data)&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;Nine&amp;#160;Months&amp;#160;Ended&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;June&amp;#160;28,&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font size="1" face="Times New Roman"&gt;&lt;b&gt;2008&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Net revenue&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;1,268,892&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Net income&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;158,959&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Net income per common share:&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Basic&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;0.63&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Diluted&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;0.61&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- 6 Last_Row * DO NOT REMOVE OR EDIT --&gt;&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font size=
"1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The $370,000 charge for
acquired in-process research and development, the fair value of the
inventory step-up of $42,300, stock-based compensation of $60,000,
direct acquisition fees and expenses of $28,000 and change of
control payments of $18,600 that were a direct result of the
transaction are excluded from the unaudited pro-forma information
above. The unaudited pro-forma results are not necessarily
indicative of the results that the Company would have attained had
the merger with Cytyc occurred at the beginning of the period
presented.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;Prior to the close of the
merger, the Board of Directors of Cytyc approved a modification to
certain outstanding equity awards for Cytyc employees, which was
consented to by the Company. The modification provided for the
acceleration of vesting upon the close of the merger for those
awards that did not provide for acceleration upon a change of
control as part of the original terms of the award. This
modification was consented to by the Company so that the Company
would not incur stock-based compensation charges that it otherwise
would have if the awards had continued to vest under their original
terms.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;

</us-gaap:BusinessCombinationDisclosureTextBlock>
  <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font size="2"
face="Times New Roman"&gt;&lt;b&gt;(18) Sale of Gestiva&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;On January&amp;#160;16, 2008, the
Company entered into a definitive agreement pursuant to which it
agreed to sell full U.S. and world-wide rights to Gestiva to K-V
Pharmaceutical Company upon approval of the pending Gestiva new
drug application (the &amp;#8220;Gestiva NDA&amp;#8221;) by the FDA. The
purchase price to be paid to the Company as a result of the
transaction is $82,000 in cash, of which $9,500 was paid in fiscal
2008 and the balance is due upon final approval by the FDA of the
Gestiva NDA on or before February 19, 2010 and the production of a
quantity of Gestiva suitable to enable the commercial launch of the
product. The Company has agreed to continue its efforts to obtain
FDA approval of the NDA for Gestiva as part of this arrangement.
All costs incurred in these efforts will be reimbursed by K-V
Pharmaceutical and are being recorded as a credit against research
and development expenses. The Company has recorded the $9,500 as a
deferred gain within current liabilities in the accompanying
Consolidated Balance Sheet. The gain will be recognized upon the
closing of the transaction following final FDA approval of the
Gestiva NDA. The Company cannot assure that it will be able to
obtain the requisite FDA approval, that the transaction will be
completed or that it will receive the balance of the purchase
price.&amp;#160;Moreover, if K-V Pharmaceutical terminates the
agreement as a result of a breach by the Company of a material
representation, warranty, covenant or agreement, the Company will
be required to return the funds previously received as well as
expenses reimbursed by K-V.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The development of Gestiva, a
drug that, if approved by the FDA, could be used in the prevention
of preterm birth in pregnant women with a history of at least one
spontaneous preterm birth, was originally begun by Adeza Biomedical
Corporation, which was acquired by Cytyc on April&amp;#160;2, 2007. On
October&amp;#160;22, 2007, the Company completed its business
combination transaction with Cytyc and as a result acquired all
rights to Gestiva. The Company allocated $53,400 to acquired
in-process research and development as part of the initial purchase
price allocation.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;

</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USDperShareItemType" decimals="2">-8.62</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USDperShareItemType" decimals="2">-8.62</us-gaap:EarningsPerShareDiluted>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font size="2"
face="Times New Roman"&gt;&lt;b&gt;(7) Commitments and
Contingencies&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&lt;u&gt;(a) Contingent Earn-Out
Payments&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;As a result of the Cytyc
merger, the Company assumed the obligation to the former Adiana
stockholders to make contingent earn-out payments tied to the
achievement of milestones. The milestone payments include potential
contingent payments of up to $155,000 based on worldwide sales of
the Adiana Permanent Contraception product in the first year
following FDA approval and on annual incremental sales growth
thereafter through December&amp;#160;31, 2012. As FDA approval had not
occurred as of June&amp;#160;27, 2009, no amounts had been recorded or
paid as of June&amp;#160;27, 2009. FDA approval was received on
July&amp;#160;6, 2009, and the Company will begin accruing contingent
consideration in the fourth quarter of fiscal 2009 based on the
defined percentage of worldwide sales of the product. These amounts
will be recorded as additional purchase price, and under the terms
of the agreement the first payment is not expected to be due until
October 2010.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The Company satisfied its
obligation for a second and final earn-out to the former Suros
Surgical Systems, Inc. (&amp;#8220;Suros&amp;#8221;) stockholders related
to Suros&amp;#8217; incremental revenue growth for revenues earned
through July&amp;#160;31, 2008. The Company accrued an amount of
approximately $24,500 for this second annual earn-out in the fourth
quarter of 2008, with an increase to goodwill, which was paid in
full as of December&amp;#160;27, 2008. The Company had also made a
payment of approximately $19,000 to the former Suros stockholders
in the fourth quarter of fiscal 2007 for the first year
earn-out.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font size=
"1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The Company also has an
obligation for up to two annual earn-out payments not to exceed
$15,000 in the aggregate based on BioLucent&amp;#8217;s achievement of
certain revenue targets. The Company has considered the provisions
of EITF Issue No.&amp;#160;95-8, &lt;i&gt;Accounting for Contingent
Consideration Paid to the Shareholders of an Acquired Enterprise in
a Purchase Business Combination&lt;/i&gt;, and concluded that this
contingent consideration will represent additional purchase price.
As a result, goodwill will be increased by the amount of the
additional consideration, if any, when it becomes due and payable.
As of June&amp;#160;27, 2009, the revenue targets had not been achieved
and the Company has not recorded any amounts for these potential
earn-outs.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:ComprehensiveIncomeNoteTextBlock contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font face=
"Times New Roman" size="2"&gt;&lt;b&gt;(11) Comprehensive Income
(Loss)&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;The Company&amp;#8217;s other
comprehensive income (loss) comprise foreign currency translation
adjustments and deferred tax on minimum pension liability. A
reconciliation of comprehensive income (loss) is as
follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; FONT-SIZE: 12px; MARGIN-BOTTOM: 0px"&gt;
&amp;#160;&lt;/p&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" align="center"
border="0"&gt;&lt;!-- 5 First_Row * DO NOT REMOVE OR EDIT --&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="68%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle" colspan="5"&gt;&lt;font face="Times New Roman" size="1"&gt;&lt;b&gt;Three
Months Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle" colspan="6"&gt;&lt;font face="Times New Roman" size="1"&gt;&lt;b&gt;Nine
Months Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle" colspan="2"&gt;&lt;font face="Times New Roman" size=
"1"&gt;&lt;b&gt;June&amp;#160;27,&lt;br /&gt;
2009&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle" colspan="2"&gt;&lt;font face="Times New Roman" size=
"1"&gt;&lt;b&gt;June&amp;#160;28,&lt;br /&gt;
2008&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle" colspan="2"&gt;&lt;font face="Times New Roman" size=
"1"&gt;&lt;b&gt;June&amp;#160;27,&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font face="Times New Roman" size="1"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle" colspan="2"&gt;&lt;font face="Times New Roman" size=
"1"&gt;&lt;b&gt;June&amp;#160;28,&lt;br /&gt;
2008&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Net income (loss) as reported&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;41,000&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;61,379&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;(2,211,177&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;(241,244&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Translation adjustment&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;3,865&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;(170&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;(1,514&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;5,200&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Deferred tax on minimum pension
liability&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;295&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;(670&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Comprehensive income (loss)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;44,865&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;61,504&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;(2,212,691&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;(236,714&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;


&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
  <us-gaap:DebtDisclosureTextBlock contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font size="2"
face="Times New Roman"&gt;&lt;b&gt;(6) Indebtedness&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&lt;u&gt;(a) Credit Agreement&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;In connection with its
acquisition of Third Wave, on July&amp;#160;17, 2008 the Company
entered into an amended and restated credit agreement (the
&amp;#8220;Amended Credit Agreement&amp;#8221;) with Goldman Sachs Credit
Partners L.P. and certain other lenders (collectively, the
&amp;#8220;Lenders&amp;#8221;). The Amended Credit Agreement amended and
restated the Company&amp;#8217;s existing credit agreement with the
Lenders, dated as of October&amp;#160;22, 2007.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;Pursuant to the terms and
conditions of the Amended Credit Agreement, the Lenders committed
to provide senior secured financing in an aggregate amount of up to
$800,000. The credit facility consisted of a $400,000 senior
secured tranche A term loan (&amp;#8220;Term Loan A&amp;#8221;); a $200,000
senior secured tranche B term loan (&amp;#8220;Term Loan B&amp;#8221;); and
a $200,000 senior secured revolving credit facility (the
&amp;#8220;Revolving Facility&amp;#8221;).&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;In order to complete the
acquisition of Third Wave, the Company borrowed $540,000 under the
credit facilities on July&amp;#160;17, 2008, consisting of $400,000
under the Term Loan A and $140,000 under the Term Loan B. As of
June&amp;#160;27, 2009, the Company had an aggregate of $269,693 of
principal outstanding under this credit facility of which $194,419
was under the Term Loan A and $75,274 was under the Term Loan B.
The long-term portion of the Term Loan A and Term Loan B loans were
$173,401 and $74,187, respectively, at June&amp;#160;27, 2009.
Subsequent to June&amp;#160;27, 2009, the Company paid down
approximately $56,000 of the outstanding principal. The Company had
no amounts outstanding under its Revolving Facility, and therefore,
had full availability of the $200,000 Revolving Facility as of
June&amp;#160;27, 2009. The final maturity dates for the credit
facility are September&amp;#160;30, 2012 for the Term Loan A and
Revolving Facility and March&amp;#160;31, 2013 for the Term Loan
B.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The domestic subsidiaries of
the Company which are party to the Amended Credit Agreement
(including Third Wave, which joined as a party to the Amended
Credit Agreement on July&amp;#160;24, 2008) have guaranteed the
Company&amp;#8217;s obligations under the credit facilities and the
credit facilities are secured by first-priority liens on, and
first-priority security interests in, substantially all of the
assets of the Company and all subsidiaries party to the Amended
Credit Agreement, a first priority security interest in 100% of the
capital stock issued by each guarantor, 65% of the capital stock
issued by certain first-tier foreign subsidiaries of the Company
and all intercompany debt. The security interests are evidenced by
an Amended and Restated Pledge and Security Agreement by and among
Goldman Sachs Credit Partners L.P., as collateral agent, Hologic
and the other parties therein named (the &amp;#8220;Amended Pledge and
Security Agreement&amp;#8221;). The Amended Pledge and Security
Agreement amended and restated Hologic&amp;#8217;s existing Pledge and
Security Agreement by and among Goldman Sachs Credit Partners L.P.,
as collateral agent, Hologic and the other parties therein named,
dated as of October&amp;#160;22, 2007.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;All amounts outstanding under
the amended credit facilities bear interest, at Hologic&amp;#8217;s
option, as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;With respect to loans made
under the Revolving Facility and the Term Loan A
facility:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 6px"&gt;
&amp;#160;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0"
cellpadding="0" width="100%"&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="13%"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="4%" align="left"&gt;&lt;font size="2" face=
"Times New Roman"&gt;(i)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" align="left"&gt;&lt;font size="2" face=
"Times New Roman"&gt;at the Base Rate plus 1.25%&amp;#160;per annum, which
was reduced from 1.50% in May 2009; or&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 6px"&gt;
&amp;#160;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0"
cellpadding="0" width="100%"&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="13%"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="4%" align="left"&gt;&lt;font size="2" face=
"Times New Roman"&gt;(ii)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" align="left"&gt;&lt;font size="2" face=
"Times New Roman"&gt;at the reserve adjusted Eurodollar Rate plus
2.25%&amp;#160;per annum, which was reduced from 2.50% in May 2009;
and&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;With respect to loans made
under the Term Loan B facility:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 6px"&gt;
&amp;#160;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0"
cellpadding="0" width="100%"&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="13%"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="4%" align="left"&gt;&lt;font size="2" face=
"Times New Roman"&gt;(i)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" align="left"&gt;&lt;font size="2" face=
"Times New Roman"&gt;at the Base Rate plus 2.25%&amp;#160;per annum;
or&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 6px"&gt;
&amp;#160;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0"
cellpadding="0" width="100%"&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="13%"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="4%" align="left"&gt;&lt;font size="2" face=
"Times New Roman"&gt;(ii)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" align="left"&gt;&lt;font size="2" face=
"Times New Roman"&gt;at the reserve adjusted Eurodollar Rate plus
3.25%&amp;#160;per annum.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The margin applicable to
loans under the Revolving Facility and the Term Loan A is subject
to specified changes based on certain changes in the leverage ratio
as specified in the Amended Credit Agreement.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;Interest accruing at the base
rate generally is payable by the Company on a quarterly basis.
Interest accruing at the Eurodollar Rate is payable on the last day
of selected interest periods (which shall be one, two, three and
six months and in certain circumstances, nine or twelve months)
unless the interest period exceeds three months, in which case,
interest will be due at the end of every three months.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font size=
"1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;Borrowings outstanding under
the Amended Credit Agreement during the three and nine months ended
June&amp;#160;27, 2009 had a weighted average interest rate of 2.77%
and 3.97%, respectively. At June&amp;#160;27, 2009, the interest rates
on the outstanding Term Loan A borrowings ranged from 2.625% to
4.5% and on the Term Loan B borrowings ranged from 3.625% to 5.5%.
Interest expense under the Amended Credit agreement for the term
loans totaled $6,507 and $18,813 during the three and nine months
ending June&amp;#160;27, 2009, respectively, which included non-cash
interest expense of $3,973 and $7,229, respectively, related to the
amortization of the capitalized deferred financing costs related to
this facility. As of June&amp;#160;27, 2009, there was $9,903 in
deferred financing costs related to the Term Loans classified as
Other Assets on the Company&amp;#8217;s Consolidated Balance
Sheets.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;Interest expense under the
Amended Credit Agreement for the Revolving Facility totaled $467
and $1,451 during the three and nine months ended June&amp;#160;27,
2009, respectively, consisting of commitment fees on the unused
portion of this facility and non-cash interest expense of $247 and
$734 related to the amortization of capitalized deferred financing
costs. As of June&amp;#160;27, 2009, there was $3,221 in deferred
financing costs related to the Revolving Facility classified as
Other Assets on the Company&amp;#8217;s Consolidated Balance Sheets.
The Company pays a quarterly commitment fee, at a per annum rate of
0.375%, which was reduced from 0.50% in May 2009, on the undrawn
commitments available under the Revolving Facility, which per annum
rate is subject to reduction based on a leverage ratio as specified
in the Amended Credit Agreement.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;Borrowings under the original
credit agreement from initial drawdown at October&amp;#160;22, 2007
through June&amp;#160;28, 2008 had a weighted average interest rate of
4.96%. Interest expense under these credit facilities totaled
approximately $3,500 and $40,400 during the three and nine months
ended June&amp;#160;28, 2008, respectively, which included non-cash
interest expense of approximately $2,200 and $12,100 related to the
amortization of the capitalized deferred financing
costs.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The credit facilities contain
affirmative and negative covenants customarily applicable to senior
secured credit facilities, including financial covenants which
require the Company to maintain maximum leverage and minimum
interest coverage ratios, as of the last day of each fiscal
quarter. The Company was in compliance with all covenants as of
June&amp;#160;27, 2009.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font size="2"
face="Times New Roman"&gt;&lt;u&gt;(b) Convertible Notes&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;On December&amp;#160;10, 2007,
the Company issued and sold $1,725,000 aggregate original principal
amount of 2.00% Convertible Senior Notes due 2037 (the
&amp;#8220;Convertible Notes&amp;#8221;). The Convertible Notes were
registered under an effective Registration Statement and were
issued pursuant to an Indenture between the Company and Wilmington
Trust Company, as Trustee (the &amp;#8220;Indenture&amp;#8221;) and a First
Supplemental Indenture thereto (the &amp;#8220;Supplemental
Indenture&amp;#8221;), both dated December&amp;#160;10, 2007.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;Holders may require the
Company to repurchase the Convertible Notes on December&amp;#160;13 of
2013, and each of December&amp;#160;15, 2017, 2022, 2027 and 2032 at a
repurchase price equal to 100% of their accreted principal amount,
plus accrued and unpaid interest. The Company may redeem any of the
Convertible Notes beginning December&amp;#160;18, 2013, by giving
holders at least 30 days&amp;#8217; notice. The Company may redeem the
Convertible Notes either in whole or in part at a redemption price
equal to 100% of their principal amount, plus accrued and unpaid
interest, including contingent interest and liquidated damages, if
any, to, but excluding, the redemption date.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;Interest expense under the
Convertible Notes totaled $9,727 and $30,171 during the three and
nine months ended June&amp;#160;27, 2009, respectively, which included
non-cash interest expense of $1,501 and $4,503, respectively,
related to the amortization of the capitalized deferred financing
costs related to the Convertible Notes Agreement. Interest expense
under the Convertible Notes totaled $9,935 and $22,249 during the
three and nine months ended June&amp;#160;28, 2008, respectively, which
included non-cash interest expense of $1,502 and $3,275,
respectively, related to the amortization of the capitalized
deferred financing costs related to the Convertible Notes
Agreement. As of June&amp;#160;27, 2009, there was $26,748 in deferred
financing costs related to the Convertible Notes classified as
Other Assets on the Company&amp;#8217;s Consolidated Balance
Sheets.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The Convertible Notes bear
interest at a rate of 2.00%&amp;#160;per year on the principal amount,
payable semi-annually in arrears in cash on June&amp;#160;15 and
December&amp;#160;15 of each year, beginning June&amp;#160;15, 2008 and
ending on December&amp;#160;15, 2013. The Convertible Notes will
accrete principal from December&amp;#160;15, 2013 at a rate that
provides holders with an aggregate annual yield to maturity of
2.00%&amp;#160;per year. Beginning with the six month interest period
commencing December&amp;#160;15, 2013, the Company will pay contingent
interest during any six month interest period to the holders of
Convertible Notes if the &amp;#8220;trading price&amp;#8221;, as defined,
of the Convertible Notes for each of the five trading days ending
on the second trading day immediately preceding the first day of
the applicable six month interest period equals or exceeds 120% of
the accreted principal amount of the Convertible Notes.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The holders of the
Convertible Notes may convert the notes into shares of the
Company&amp;#8217;s common stock at a conversion price of approximately
$38.60 per share, subject to adjustment, prior to the close of
business on September&amp;#160;15, 2037, subject to prior redemption or
repurchase of the notes, upon the occurrence of certain events, as
defined. None of the events that would allow the holders to convert
prior to September&amp;#160;15, 2037 have occurred to date.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;In lieu of delivery of shares
of the Company&amp;#8217;s common stock in satisfaction of the
Company&amp;#8217;s obligation upon conversion of the Convertible
Notes, the Company may elect to deliver cash or a combination of
cash and shares of the Company&amp;#8217;s common stock. If&lt;/font&gt;
&lt;font size="2" face="Times New Roman"&gt;the Company elects to satisfy
its conversion obligation in a combination of cash and shares of
the Company&amp;#8217;s common stock, the Company is required to
deliver up to a specified dollar amount of cash per $1,000 original
principal amount of Convertible Notes, and will settle the
remainder of the conversion obligation in shares of its common
stock, in each case as provided in the Indenture. It is the
Company&amp;#8217;s current intent and policy to settle any conversion
of the Convertible Notes as if the Company had elected to make the
net share settlement election.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The Convertible Notes are the
Company&amp;#8217;s senior unsecured obligations and rank equally with
all of the Company&amp;#8217;s existing and future senior unsecured
debt and prior to all future subordinated debt. The Convertible
Notes are effectively subordinated to any future secured
indebtedness to the extent of the collateral securing such
indebtedness, and structurally subordinated to all indebtedness and
other liabilities (including trade payables) of the Company&amp;#8217;s
subsidiaries.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;If an event of default, as
defined, relates to the Company&amp;#8217;s failure to comply with the
reporting obligations in the Convertible Notes, if the Company so
elects, the sole remedy of the holders of the Convertible Notes for
the first 90 days following such event of default consists
exclusively of the right to receive an extension fee on the notes
in an amount equal to 0.25% of the accreted principal amount of the
Convertible Notes.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;Based on the Company&amp;#8217;s
evaluation of the Convertible Notes in accordance with EITF Issue
No. 00-19, &lt;i&gt;Accounting for Derivative Financial Instruments
Indexed to, and Potentially Settled in, a Company&amp;#8217;s Own
Stock&lt;/i&gt;, and SFAS No.&amp;#160;133, &lt;i&gt;Accounting for Derivative
Instruments and Hedging Activities&lt;/i&gt; (&amp;#8220;SFAS 133&amp;#8221;),
the Company determined that the Convertible Notes contained a
single embedded derivative, comprising both the contingent interest
feature and the filing failure penalty payment requiring
bifurcation as the features were not clearly and closely related to
the host instrument. The Company has determined that the value of
this embedded derivative was nominal for all periods presented in
the consolidated financial statements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;As of June&amp;#160;27, 2009,
upon conversion, including the potential premium that could be
payable on a fundamental change (as defined), the Company would
issue a maximum of approximately 56,000 common shares to the
Convertible Note holders.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;See Note 19, &amp;#8220;Recent
Accounting Pronouncements&amp;#8221;, for a discussion related to the
impact of the adoption of FASB Staff Position Accounting Principles
Board (&amp;#8220;APB&amp;#8221;) 14-1, &lt;i&gt;Accounting for Convertible Debt
Instruments that May Be Settled in Cash upon Conversion (Including
Partial Cash Settlement)&lt;/i&gt; in fiscal 2010.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font size="2"
face="Times New Roman"&gt;&lt;u&gt;(c) AEG Debt&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The Company&amp;#8217;s AEG
subsidiary has approximately $9,000 outstanding at June&amp;#160;27,
2009 under certain debt agreements of which the long term portion
is approximately $7,100. The terms of the agreements have various
maturities ranging from December&amp;#160;30, 2010 through
March&amp;#160;30, 2014. Outstanding borrowings had interest rates
ranging from 2.1% to 4.3% and 5.5% to 7.2% during the nine months
ended June&amp;#160;27, 2009 and June&amp;#160;28, 2008, respectively.
Interest expense incurred under these debt agreements totaled $75
and $314 during the three and nine months ended June&amp;#160;27, 2009,
respectively, and $174 and $572 during the three and nine months
ended June&amp;#160;28, 2008, respectively. Subsequent to June&amp;#160;27,
2009, the Company paid off approximately $7,200 of the outstanding
principal balance under these debt agreements.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;

</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:AmortizationOfFinancingCosts contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">12466000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">38356000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AdjustmentForAmortization contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">154635000</us-gaap:AdjustmentForAmortization>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">352040000</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSoldAmortization contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">116279000</us-gaap:CostOfGoodsSoldAmortization>
  <us-gaap:CostOfServices contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">111305000</us-gaap:CostOfServices>
  <us-gaap:CostsAndExpenses contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3" id="fnid_453490_3_17">3326752000</us-gaap:CostsAndExpenses>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">2797000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:Depreciation contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">48651000</us-gaap:Depreciation>
  <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font size="2"
face="Times New Roman"&gt;&lt;b&gt;(10) Stock-Based
Compensation&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;Stock-based compensation
expense from the issuance of stock options and restricted stock
units in the three and nine months ended June&amp;#160;27, 2009 and
June&amp;#160;28, 2008 is as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#160;&lt;/p&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" width="100%"
align="center"&gt;&lt;!-- 5 First_Row * DO NOT REMOVE OR EDIT --&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="73%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="5" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;Three&amp;#160;Months&amp;#160;Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="5" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;Nine Months Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;June&amp;#160;27,&lt;br /&gt;
2009&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;June&amp;#160;28,&lt;br /&gt;
2008&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;June&amp;#160;27,&lt;br /&gt;
2009&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;June&amp;#160;28,&lt;br /&gt;
2008&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Cost of revenues&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;913&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;508&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;2,625&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;1,751&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Research and development&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;747&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;553&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;3,095&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;1,782&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Selling and marketing&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;1,228&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;907&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;4,005&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;2,402&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;General and administrative&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;5,122&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;3,073&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;14,628&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;11,612&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Restructuring charge&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;1,941&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;1,941&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;8,010&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;6,982&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;24,353&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;19,488&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- 6 Last_Row * DO NOT REMOVE OR EDIT --&gt;&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font size="2"
face="Times New Roman"&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The Company granted 2,969 and
3,216 stock options, respectively, during the nine months ended
June&amp;#160;27, 2009 and June&amp;#160;28, 2008 with weighted average
exercise prices of $14.42 and $32.87, respectively. There were
16,116 options outstanding at June&amp;#160;27, 2009 with a weighted
average exercise price of $15.88.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font size=
"1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The Company uses a binomial
model to determine the fair value of its stock options. The
weighted-average assumptions utilized to value these stock options
are indicated in the following table:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#160;&lt;/p&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" width="100%"
align="center"&gt;&lt;!-- 5 First_Row * DO NOT REMOVE OR EDIT --&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="71%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="6" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;Three&amp;#160;Months&amp;#160;Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="6" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;Nine&amp;#160;Months&amp;#160;Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;June&amp;#160;27,&lt;br /&gt;
2009&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;June&amp;#160;28,&lt;br /&gt;
2008&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;June&amp;#160;27,&lt;br /&gt;
2009&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;June&amp;#160;28,&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font size="1" face="Times New Roman"&gt;&lt;b&gt;2008&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;2.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;3.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;2.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;3.0%&amp;#160;to&amp;#160;4.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;46.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;36.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;46.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;36.0%&amp;#160;to&amp;#160;38.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Expected life (in years)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;4.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;3.8&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;4.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;3.8 to 4.6&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Dividend yield&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Forfeiture rate&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;7.7&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;6.8&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;7.7&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;6.8%&amp;#160;to&amp;#160;9.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Weighted average fair value of stock options
granted&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;5.10&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;9.65&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;5.40&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;10.38&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- 6 Last_Row * DO NOT REMOVE OR EDIT --&gt;&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;Included in stock-based
compensation expense for the nine months ended June&amp;#160;28, 2008
was $2,662 as a result of the acceleration of vesting for certain
outstanding Hologic stock options upon the close of the merger with
Cytyc. The original terms of these employee stock options provided
for acceleration of vesting upon a change of control. In addition,
stock-based compensation expense during the nine months ended
June&amp;#160;28, 2008 included $2,264 as a result of a modification of
certain stock options in connection with the Cytyc Merger Agreement
in May 2007. The modification provided for acceleration of vesting
of the unvested options upon a termination as a result of a change
of control, as well as an extension of the period to exercise
vested options from 90 days to December&amp;#160;31, 2009, which
occurred upon the close of the merger with Cytyc. The Company also
recorded additional stock-based compensation expense of $768 during
the three months ended June&amp;#160;28, 2008 for options issued to the
former Chairman of the Board of Directors that were modified to
extend the time period to exercise upon termination from 90 days to
August&amp;#160;31, 2009.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;As of June&amp;#160;27, 2009,
total unrecognized compensation expense related to stock options is
$30,723, which is expected to be recognized over a weighted average
period of 3.7 years&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font size="2"
face="Times New Roman"&gt;&lt;i&gt;Restricted Stock Units&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The Company granted 1,669 and
1,226 restricted stock units, respectively, during the nine months
ended June&amp;#160;27, 2009 and June&amp;#160;28, 2008, respectively, with
weighted average grant date fair values of $14.46 and $33.23 per
share, respectively. As of June&amp;#160;27, 2009, there were 2,815
unvested restricted stock units outstanding with a weighted average
grant date fair value of $21.94.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The estimated forfeiture rate
for restricted stock awards used in determining the expense
recorded in the Company&amp;#8217;s Consolidated Statements of
Operations was 6.4% and 7.0% for the nine months ended
June&amp;#160;27, 2009 and June&amp;#160;28, 2008, respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;Stock-based compensation
expense for the nine months ended June&amp;#160;27, 2009 and
June&amp;#160;28, 2008 for restricted stock units included $41 and
$570, respectively, as a result of the acceleration of vesting for
certain outstanding restricted stock units in connection with the
acquisition of Third Wave and the merger with Cytyc,
respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;As of June&amp;#160;27, 2009,
total unrecognized compensation expense related to restricted stock
units is $36,064, which is expected be recognized over a weighted
average period of 2.6 years.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font size="2"
face="Times New Roman"&gt;&lt;i&gt;Employee Stock Purchase
Plan&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;At the Company&amp;#8217;s
March&amp;#160;11, 2008 Annual Meeting of Stockholders, the
Company&amp;#8217;s 2008 Employee Stock Purchase Plan (the &amp;#8220;ESP
Plan&amp;#8221;) was approved. The plan meets the criteria set forth in
SFAS 123(R)&amp;#8217;s definition of a non-compensatory plan, and
therefore does not give rise to the recognition of stock
compensation expense. Employees who have completed three
consecutive months, or two years, whether or not consecutive, of
employment with the Company or any of its participating
subsidiaries are eligible to participate in the ESP Plan. The ESP
Plan allows participants to purchase common stock of the Company at
95% of the fair market value, as defined. A total of 400 shares may
be issued under the ESP Plan. During the second quarter of fiscal
2009, the Company issued 77 shares under the ESP Plan.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font size=
"1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&lt;i&gt;Option Exchange Program&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;On December&amp;#160;22, 2008,
the Board of Directors approved, subject to stockholder approval, a
one-time stock option exchange program (the &amp;#8220;Option Exchange
Program&amp;#8221;). The Option Exchange Program was approved at the
Annual Meeting of Stockholders held on March&amp;#160;4, 2009. The
Option Exchange Program permitted eligible employees to exchange
their outstanding options issued on January&amp;#160;16, 2008 at an
exercise price per share of $33.31 for a lesser number of new
options (&amp;#8220;New Options&amp;#8221;), with such number of New
Options issuable upon exchange calculated pursuant to an exchange
ratio based on the original exercise price of the surrendered
option. The exchange offer expired on April&amp;#160;5, 2009. Pursuant
to the Option Exchange Program, the New Options have an exercise
price of $14.87, which is 110% of the last reported closing sales
price of the Company&amp;#8217;s common stock as of the date of the new
grant, which was April&amp;#160;5, 2009. The total number of stock
options eligible to be exchanged of 784 was exchanged for 406 New
Options.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;On the date of exchange, the
estimated fair value of the New Options approximated the estimated
fair value of the exchanged stock options calculated immediately
prior to the exchange. As such, there is no incremental fair value
of the New Options, and the Company will not record additional
compensation expense related to the exchange. The Company will
continue to recognize the remaining compensation expense related to
the exchanged options over the remaining vesting period of the
original options. The New Options become exercisable over a period
of four years, with 25% vesting on the first anniversary of the
date the New Options were granted and 25% vesting on each
anniversary thereafter, so long as the option holder continues to
be employed by the Company.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;

</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">108000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">528000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">528000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
  <us-gaap:FairValueMeasurementInputsDisclosureTextBlock contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0">&lt;div&gt;
&lt;h5 align="left"&gt;&lt;/h5&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font face=
"Times New Roman" size="2"&gt;&lt;b&gt;(2) Fair Value
Measurements&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;Effective September&amp;#160;28,
2008, the Company adopted SFAS No.&amp;#160;157, &lt;i&gt;Fair Value
Measurement&lt;/i&gt; (&amp;#8220;SFAS&amp;#160;157&amp;#8221;), for its financial
assets and financial liabilities that are re-measured and reported
at fair value at each reporting period and its nonfinancial assets
and nonfinancial liabilities that are re-measured and reported at
fair value at least annually. In accordance with the provisions of
FASB Staff Position (&amp;#8220;FSP&amp;#8221;) No.&amp;#160;SFAS&amp;#160;157-2,
&lt;i&gt;Effective Date of FASB Statement No.&amp;#160;157,&lt;/i&gt; the Company
has elected to defer implementation of SFAS&amp;#160;157 as it relates
to its nonfinancial assets and nonfinancial liabilities that are
recognized and disclosed at fair value in the financial statements
on a non-recurring basis until September&amp;#160;27, 2009. The Company
is evaluating the impact, if any, SFAS 157 will have on its
nonfinancial assets and nonfinancial liabilities.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;The adoption of SFAS&amp;#160;157
for financial assets and financial liabilities that are re-measured
and reported at fair value on a recurring basis did not have an
impact on the Company&amp;#8217;s financial results.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;SFAS 157 establishes a
three-level valuation hierarchy for disclosure of fair value
measurements. Financial assets and financial liabilities are
categorized within the valuation hierarchy based upon the lowest
level of input that is significant to the measurement of fair
value. The three levels of the hierarchy are defined as
follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; FONT-SIZE: 6px; MARGIN-BOTTOM: 0px"&gt;
&amp;#160;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0"
cellpadding="0" width="100%" border="0"&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="5%"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" align="left" width="2%"&gt;&lt;font face=
"Times New Roman" size="2"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" align="left"&gt;
&lt;p align="left"&gt;&lt;font face="Times New Roman" size="2"&gt;Level 1
&amp;#8211; Inputs to the valuation methodology are quoted market
prices for identical assets or liabilities.&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 0px; FONT-SIZE: 6px; MARGIN-BOTTOM: 0px"&gt;
&amp;#160;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0"
cellpadding="0" width="100%" border="0"&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="5%"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" align="left" width="2%"&gt;&lt;font face=
"Times New Roman" size="2"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" align="left"&gt;
&lt;p align="left"&gt;&lt;font face="Times New Roman" size="2"&gt;Level 2
&amp;#8211; Inputs to the valuation methodology are other observable
inputs, including quoted market prices for similar assets or
liabilities and market-corroborated inputs.&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 0px; FONT-SIZE: 6px; MARGIN-BOTTOM: 0px"&gt;
&amp;#160;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0"
cellpadding="0" width="100%" border="0"&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="5%"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" align="left" width="2%"&gt;&lt;font face=
"Times New Roman" size="2"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" align="left"&gt;
&lt;p align="left"&gt;&lt;font face="Times New Roman" size="2"&gt;Level 3
&amp;#8211; Inputs to the valuation methodology are unobservable inputs
based on management&amp;#8217;s best estimate of inputs market
participants would use in pricing the asset or liability at the
measurement date, including assumptions about risk.&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;As of June&amp;#160;27, 2009, the
Company&amp;#8217;s financial assets that are re-measured at fair value
on a recurring basis consisted of $7,710 in money market mutual
funds that are classified as cash and cash equivalents in the
Consolidated Balance Sheets. As there are no withdrawal
restrictions, they are classified within Level&amp;#160;1 of the fair
value hierarchy and are valued using quoted market prices for
identical assets.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;The Company holds certain
minority cost-method equity investments in non-publicly traded
securities aggregating $7,435 and $9,278 at June&amp;#160;27, 2009 and
September&amp;#160;27, 2008, respectively, which are included in other
long-term assets on the Company&amp;#8217;s Consolidated Balance
Sheets. These investments are generally carried at cost as the
Company owns less than 20% of the voting equity and does not have
the ability to exercise significant influence over these companies.
The Company regularly evaluates the carrying value of its
cost-method investments for impairment and whether any events or
circumstances are identified that would significantly harm the fair
value of the investment. The indicators the Company utilizes to
identify these events and circumstances include (1)&amp;#160;the
investee&amp;#8217;s revenue or earnings trends compared to budgets and
pre-defined milestones, (2)&amp;#160;the technological feasibility of
the investee&amp;#8217;s products and technologies, (3)&amp;#160;general
market conditions in the investee&amp;#8217;s industry including
adverse regulatory or economic changes, (4)&amp;#160;factors related to
the investee&amp;#8217;s ability to remain in business, such as the
investee&amp;#8217;s liquidity and rate of cash use, and (5)&amp;#160;the
investee&amp;#8217;s ability to secure additional funding and the value
of that additional funding. In the event a decline in fair value is
judged to be other-than-temporary, the Company will record an
other-than-temporary impairment charge in Other income (expense),
net in the Consolidated Statements of Operations. As the inputs
utilized for the impairment assessment are not based on observable
market data, these cost method investments are classified within
Level 3 of the fair value hierarchy on a non-recurring basis. To
determine the fair value of these investments, the Company uses all
available financial information related to the entities, including
information based on recent or pending third-party equity
investments in these entities. During the three months ended
June&amp;#160;27, 2009, the Company recorded an other-than-temporary
impairment charge of $1,933 on one of its cost-method investments
to fully write-off the carrying value of the investment. During the
nine months ended June&amp;#160;27, 2009, the Company recorded an
other-than-temporary impairment charge totaling $2,243 related to
two of its cost method investments to adjust their carrying amounts
to fair value.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;

</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">-2676000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">110654000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font size="2"
face="Times New Roman"&gt;&lt;b&gt;(17)&amp;#160;Goodwill and Intangible
Assets&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%"&gt;
&lt;font size="2" face="Times New Roman"&gt;&lt;i&gt;Goodwill&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;In accordance with SFAS
No.&amp;#160;142, &lt;i&gt;Goodwill and Other Intangible Assets&lt;/i&gt;
(&amp;#8220;SFAS 142&amp;#8221;)&lt;i&gt;,&lt;/i&gt; the Company tests goodwill at the
reporting unit level for impairment on an annual basis and between
annual tests if events and circumstances indicate it is more likely
than not that the fair value of a reporting unit is less than its
carrying value. Events that would indicate impairment and trigger
an interim impairment assessment include, but are not limited to,
current economic and market conditions, a significant adverse
change in legal factors, business climate or operational
performance of the business, and an adverse action or assessment by
a regulator.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;In performing the impairment
test, the Company utilizes the two-step approach prescribed under
SFAS 142. The first step requires a comparison of the carrying
value of the reporting units to the estimated fair value of the
reporting units. To estimate the fair value of its reporting units
for Step 1, the Company utilizes a combination of the income and
market approaches and performs a valuation analysis. The income
approach is based on a discounted cash flow analysis
(&amp;#8220;DCF&amp;#8221;) and calculates the fair value by estimating the
after-tax cash flows attributable to a reporting unit and then
discounting the after-tax cash flows to a present value using a
risk-adjusted discount rate. Assumptions used in the DCF require
the exercise of significant judgment, including judgment about
appropriate discount rates and terminal values, growth rates, and
the amount and timing of expected future cash flows. The forecasted
cash flows are based on the Company&amp;#8217;s most recent budget and
for years beyond the budget, the Company&amp;#8217;s estimates are
based on assumed growth rates. The Company believes its assumptions
are consistent with the plans and estimates used to manage the
underlying businesses. The discount rates, which are intended to
reflect the risks inherent in future cash flow projections, used in
the DCF are based on estimates of the weighted-average cost of
capital (&amp;#8220;WACC&amp;#8221;) of a market participant relative to
each respective reporting unit. The market approach considers
comparable market data based on multiples of revenue or earnings
before taxes, depreciation and amortization (&amp;#8220;EBITDA&amp;#8221;).
The Company believes its assumptions used to determine the fair
value of its respective reporting units are reasonable. If
different assumptions were used, particularly with respect to
forecasted cash flows, WACCs, or market multiples, different
estimates of fair value may result and there could be the potential
that an impairment charge could result. Actual operating results
and the related cash flows of the reporting units could differ from
the estimated operating results and related cash flows.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font size=
"1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;If the carrying value of a
reporting unit exceeds its estimated fair value, the Company is
required to perform the second step of the goodwill impairment test
to measure the amount of impairment loss, if any. The second step
of the goodwill impairment test compares the implied fair value of
a reporting unit&amp;#8217;s goodwill to its carrying value. The
implied fair value of goodwill is derived by performing a
hypothetical purchase price allocation for each reporting unit as
of the measurement date, allocating the reporting unit&amp;#8217;s
estimated fair value to its assets and liabilities. The residual
amount from performing this allocation represents the implied fair
value of goodwill. To the extent this amount is below the carrying
value of goodwill, an impairment charge is recorded.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;In prior years, the Company
conducted its annual impairment test of goodwill for certain of its
reporting units (its historical reporting units prior to the Cytyc
merger) as of the last day of the second quarter. In the fourth
quarter of fiscal 2008, the Company changed the measurement date
from the last day of its second quarter to the first day of its
fourth quarter, in order to provide additional time to determine
the fair value of its reporting units and to evaluate the results
of the impairment testing. This change did not delay, accelerate or
avoid an impairment charge. This change did not have any effect on
the Company&amp;#8217;s financial performance or results of operations,
nor was there any impact on prior periods&amp;#8217; financial
statements under the requirements of SFAS No.&amp;#160;154,
&lt;i&gt;Accounting Changes and Error Corrections&lt;/i&gt; (&amp;#8220;SFAS
154&amp;#8221;). The retrospective application as required under
SFAS&amp;#160;154 was not necessary as no impairment charges had been
recorded in any previously recorded financial statements nor did
the change in measurement date cause any impairments.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;As a result of the change in
the measurement date for the Company&amp;#8217;s annual goodwill
impairment test for its historical reporting units from the last
day of the second quarter of the fiscal year to the first day of
the fourth quarter of the fiscal year, the Company evaluated, in
accordance with paragraph 27 of SFAS 142, whether the detailed
determination of fair value of its historical reporting units as of
March&amp;#160;29, 2008 could be carried forward to the first day of
its fiscal fourth quarter of 2008 or if a new test of goodwill
impairment was required to be performed for these historical
reporting units. In its evaluation, the Company noted that the
assets and liabilities of the reporting units had not changed
significantly, there was sufficient margin between the carrying
amount and fair value determination for each reporting unit and no
events or circumstances related to these reporting units would
suggest that a current fair value determination of reporting units
would result in a valuation lower than the carrying amount of the
reporting units. Based on this evaluation, the Company believed it
sufficiently met the requirements of paragraph 27 of SFAS 142 to
carry forward its estimate of fair value for these reporting
units.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The Company conducted its
annual impairment test of goodwill for its new reporting units as a
result of the Company&amp;#8217;s acquisition of Cytyc Corporation as
of the first day of the fourth quarter of fiscal 2008. The fair
value of each reporting unit was determined to be in excess of each
reporting unit&amp;#8217;s carrying value and as a result the second
step of the impairment test was not required.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;During the first quarter of
fiscal 2009, based upon a combination of factors, including the
deteriorating macro-economic environment, declines in the stock
market and the decline of the Company&amp;#8217;s market capitalization
significantly below the book value of the Company&amp;#8217;s net
assets, the Company concluded that potential goodwill impairment
indicators existed as of December&amp;#160;27, 2008. As a result, the
Company performed an interim goodwill impairment analysis as of
December&amp;#160;27, 2008 in accordance with SFAS 142. As noted above,
the Company has utilized DCF and market approaches to estimate the
fair value of its reporting units as of December&amp;#160;27, 2008 and
believes it has used reasonable estimates and assumptions about
future revenue, cost projections, cash flows and market multiples.
In addition, using a DCF requires the use of a risk-adjusted
discount rate for which the Company based its rate on the WACC of a
market participant. The Company performed a peer company analysis
and considered the industry weighted average return on debt and
equity from a market participant perspective for its reporting
units. Given the disruptions in the credit and equity markets, the
WACCs for each reporting unit increased between the Company&amp;#8217;s
annual test performed on the first day of its fourth quarter of
fiscal 2008 and the interim test performed as of December&amp;#160;27,
2008. The long-term growth rates are largely consistent with those
applied in the annual test performed, except for MammoSite, which
is a reporting unit in Breast Health, in which the long-term growth
rate declined due to current competitive pressures on the reporting
unit&amp;#8217;s products, as well as recent regulatory and
reimbursement changes. The Step 1 impairment analysis indicated
that the carrying value of the net assets of three of the
Company&amp;#8217;s reporting units, acquired in connection with the
Cytyc acquisition, exceeded the estimated fair value of those
reporting units. As a result, the Company was required to perform
Step 2 of the goodwill impairment test to determine the amount, if
any, of goodwill impairment charges for each of the applicable
reporting units. Due to the complexities and time involved in
preparing the Step 1 analysis, the Company had not commenced the
Step 2 analysis as of February&amp;#160;5, 2009, the date it filed its
Form 10-Q for the quarter ended December&amp;#160;27, 2008. As a result
of the fact that the Company had not commenced the Step 2 analysis
and the complexity of the analysis required to complete the Step 2
analysis, the Company was unable to determine that an impairment
loss, in accordance with SFAS No.&amp;#160;5, &lt;i&gt;Accounting for
Contingencies&lt;/i&gt;, was both probable and reasonably estimable at
December&amp;#160;27, 2008.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The Company completed the
Step 2 analysis during its second quarter of fiscal 2009, which
resulted in an aggregate goodwill impairment charge of $2,340,023.
This impairment charge is comprised of $1,165,804 for GYN Surgical,
$908,349 for Diagnostics, and $265,870 for Breast Health. The
impairment charges for GYN Surgical and Diagnostics are primarily
attributable to the assumption of higher discount rates compared to
those used in the annual impairment test performed as of the first
day of the fourth quarter of fiscal 2008 (the July 2008 valuation)
and the assumption that the reporting units would be purchased or
sold in a taxable&lt;/font&gt; &lt;font size="2" face=
"Times New Roman"&gt;transaction in accordance with EITF Issue
No.&amp;#160;02-13, &lt;i&gt;Deferred Income Tax Considerations in&lt;/i&gt;
&lt;i&gt;Applying the Goodwill Impairment Test&lt;/i&gt; &lt;i&gt;in FASB Statement
No.&amp;#160;142&lt;/i&gt; (&amp;#8220;EITF 02-13&amp;#8221;). The impairment charge
for MammoSite, which is included in Breast Health, is a result of a
combination of a higher discount rate and lower projected future
cash flows compared to those used in the July 2008 valuation. The
higher discount rates for the three reporting units, which range
from 10% to 13.5% compared to 9% to 10% used in the July 2008
valuation, reflect an increase in the risks inherent in the
estimated future cash flows and the higher rate of return a market
participant would require based on the current macro-economic
environment. The reduction in forecasted cash flows for the
MammoSite reporting unit is due to current competitive pressure on
the reporting unit&amp;#8217;s products as well as recent regulatory
and reimbursement changes.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The Company also evaluated
the aggregate fair value of its reporting units compared to its
market capitalization noting an implied control premium of
approximately 16% at December&amp;#160;27, 2008. The Company used an
average of its market capitalization over the 30 calendar days
preceding the impairment testing date as being more reflective of
its market value than a single day, point-in-time market
price.&amp;#160;The Company concluded that its implied control premium
was reasonable when compared to industry specific information.
There have been no material changes in the Company&amp;#8217;s market
capitalization from the date of the interim goodwill impairment
test as of December&amp;#160;27, 2008 through June&amp;#160;27, 2009, and
no other potential goodwill impairment indicators have been
identified that would require an additional interim goodwill
impairment test as of June&amp;#160;27, 2009.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The Company believes that the
procedures performed and the estimates and assumptions used in the
Step 1 and Step 2 analyses for each reporting unit are reasonable
and in accordance with the guidelines for acquisition accounting
under SFAS 141, SFAS 142 and EITF 02-13.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;For illustrative purposes,
had the fair values of each reporting unit for which the Company
has recorded goodwill impairment charges in the second quarter of
fiscal 2009 been lower by 10% as of December&amp;#160;27, 2008, the
Company would have recorded an additional impairment charge of
$435,480. Based on the Company&amp;#8217;s estimates as of
December&amp;#160;27, 2008, the impact of reducing the Company&amp;#8217;s
fair value estimates for its other reporting units, for which the
Company did not record any goodwill impairment charges, by 10%
would have no impact on the Company&amp;#8217;s goodwill assessment for
those reporting units.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The estimate of fair value
requires significant judgment. Any loss resulting from the SFAS 142
impairment analysis is reflected in operating income (loss) in the
Company&amp;#8217;s Consolidated Statements of Operations. The
impairment testing process is subjective and requires judgment at
many points throughout the analysis. If these estimates or their
related assumptions change in the future, the Company may be
required to record impairment charges for these assets not
previously recorded. Impairment charges related to goodwill have no
impact on the Company&amp;#8217;s cash balances or compliance with
financial covenants under its Amended and Restated Credit
Agreement.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The following table presents
the changes in goodwill during the nine months ended June&amp;#160;27,
2009:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#160;&lt;/p&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" width="68%"
align="center"&gt;&lt;!-- 5 First_Row * DO NOT REMOVE OR EDIT --&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="84%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Balance at September&amp;#160;27, 2008&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;4,450,496&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Impairment of goodwill&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;(2,340,023&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Purchase price adjustments&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;(9,291&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Foreign currency translation impact&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;(244&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Balance at June&amp;#160;27, 2009&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;2,100,938&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- 6 Last_Row * DO NOT REMOVE OR EDIT --&gt;&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The decrease of approximately
$9,300 to goodwill for purchase price adjustments during the nine
months ended June&amp;#160;27, 2009 primarily includes a $2,000
increase to the estimated tax net operating loss carryforward
acquired in the Third Wave acquisition due to finalizing the
analysis in the third quarter of fiscal 2009 of the amounts the
Company believes are more likely than not to be realized, as well
as increases to the tax net operating loss carryforwards acquired
as a result of the Cytyc and R2 acquisitions in the amounts of
$2,100 and $2,000, respectively, and an increase in the preliminary
estimate of other tax attributes acquired in the Third Wave
acquisition of $3,000.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The allocation of goodwill by
reporting segment consisted of the following:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#160;&lt;/p&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" width="76%"
align="center"&gt;&lt;!-- 5 First_Row * DO NOT REMOVE OR EDIT --&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="64%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;Balance as of&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;June&amp;#160;27,&amp;#160;2009&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;Balance as of&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;September&amp;#160;27,&amp;#160;2008&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Breast Health&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;662,617&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;930,672&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Diagnostics&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;572,147&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;1,486,988&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;GYN Surgical&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;858,000&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;2,024,639&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Skeletal Health&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;8,174&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;8,197&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;2,100,938&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;4,450,496&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- 6 Last_Row * DO NOT REMOVE OR EDIT --&gt;&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font size=
"1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%"&gt;
&lt;font size="2" face="Times New Roman"&gt;&lt;i&gt;Intangible
Assets&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The majority of the
Company&amp;#8217;s intangible assets arose in connection with its
business combinations. These intangible assets were recorded at
fair value and are stated net of accumulated amortization and
impairments. The Company amortizes its intangible assets that have
finite lives using either the straight-line method, or if reliably
determinable, based on the pattern in which the economic benefit of
the asset is expected to be consumed utilizing expected
undiscounted future cash flows. Amortization is recorded over the
estimated useful lives ranging from 2 to 30 years. If the estimate
of an intangible asset&amp;#8217;s remaining useful life is changed,
the Company will amortize the remaining carrying value of the
intangible asset prospectively over the revised remaining useful
life.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;Subsequent to the Cytyc
merger, the Company decided to discontinue the development of
Cytyc&amp;#8217;s Helica product. The Company will not realize any
future cash flows from this product. The Company&amp;#8217;s intangible
asset valuation for Cytyc included approximately $2,900 related to
customer relationships for Helica. As a result of the Helica
product discontinuation, the Company recorded an impairment charge,
as a component of its GYN Surgical segment, of $2,900 in the first
quarter of fiscal 2008.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;In accordance with SFAS
No.&amp;#160;144, &lt;i&gt;Accounting for the Impairment or Disposal of
Long-Lived Assets&lt;/i&gt; (&amp;#8220;SFAS 144&amp;#8221;), the Company
evaluates the realizability of long-lived assets, which primarily
consist of property and equipment and definite lived intangible
assets (the &amp;#8220;SFAS 144 Long-Lived Assets&amp;#8221;), whenever
events or changes in circumstances or business conditions indicate
that the carrying value of the long-lived assets may not be
recoverable based on expectations of undiscounted future cash flows
for each asset group. As a result of the Company&amp;#8217;s conclusion
that an interim impairment test of goodwill was required during the
first quarter of fiscal 2009 (as discussed above), the Company
performed an interim test for the impairment of long-lived assets
as required by SFAS 144 in the first quarter of fiscal
2009.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The interim evaluation of the
impairment of long-lived assets, other than goodwill, was based on
expectations of undiscounted future cash flows compared to the
carrying value of the long-lived asset groups in accordance with
SFAS 144. If the sum of the expected undiscounted future cash flows
was less than the carrying amount of the SFAS 144 Long-Lived
Assets, the Company would recognize an impairment loss. The
Company&amp;#8217;s cash flow estimates were based upon historical cash
flows, as well as future projected cash flows derived from the
annual Company wide planning process and interim forecasting. The
Company believes that its procedures for estimating gross future
cash flows are reasonable and consistent with market conditions at
the time of estimation. The results of the Company&amp;#8217;s interim
impairment testing under SFAS 144 indicated that there was no
impairment of SFAS 144 Long-Lived Assets as of December&amp;#160;27,
2008.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;During the second quarter of
fiscal 2009, the Company decided to discontinue selling a certain
product within the Diagnostic reporting segment as a result of
recent communications from the FDA regarding the approval process.
The Company believes that its decision is an indicator of
impairment, and therefore, the Company performed an impairment test
in accordance with SFAS 144. The Company determined that the
undiscounted cash flows to be generated by the asset group over its
remaining estimated useful life would not be sufficient to recover
the carrying value of the asset group. Due to the insufficient cash
flows to be generated, the Company determined that the asset
group&amp;#8217;s fair value was de minimus and recorded an impairment
charge of $4,065 comprised of developed technology of $2,594 and
capitalized license fees of $1,471. This charge is reflected in
cost of product sales in the Company&amp;#8217;s Consolidated Statement
of Operations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;During the third quarter of
fiscal 2009, the Company acquired certain developed technology of
approximately $5,400.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;Intangible assets consist of
the following:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#160;&lt;/p&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" width="100%"
align="center"&gt;&lt;!-- 5 First_Row * DO NOT REMOVE OR EDIT --&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="51%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
rowspan="2" nowrap="nowrap"&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 1px"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;Description&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
rowspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;Weighted&amp;#160;Average&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font size="1" face="Times New Roman"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font size="1" face="Times New Roman"&gt;&lt;b&gt;Estimated&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;Amortization&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;Period&amp;#160;(in&amp;#160;years)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="5" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;As&amp;#160;of&amp;#160;June
27,&amp;#160;2009&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="5" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;As&amp;#160;of&amp;#160;September&amp;#160;27,&amp;#160;2008&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font size="1" face="Times New Roman"&gt;&lt;b&gt;Carrying&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font size="1" face="Times New Roman"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;Accumulated&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;Amortization&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font size="1" face="Times New Roman"&gt;&lt;b&gt;Carrying&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font size="1" face="Times New Roman"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;Accumulated&lt;br /&gt;
Amortization&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Developed&amp;#160;Technology&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;12.9&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;2,137,621&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;228,121&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;2,135,688&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;112,568&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Customer Relationship&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;12.9&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;484,852&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;53,179&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;484,136&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;22,509&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Trade Name&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;23.4&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;146,946&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;17,552&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;146,963&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;9,950&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Patents&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;9.8&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;11,449&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;7,710&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;11,183&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;7,544&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Capitalized License Fees&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;6.1&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;2,766&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;413&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;6,491&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;2,239&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Totals&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;2,783,634&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;306,975&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;2,784,461&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;154,810&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- 6 Last_Row * DO NOT REMOVE OR EDIT --&gt;&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;Amortization expense related
to developed technology, capitalized license fees and patents is
classified as a component of cost of product sales &amp;#8211;
amortization of intangible assets in the accompanying Consolidated
Statements of Operations. Amortization expense related to customer
relationship and trade name is classified as a component of
amortization of acquired intangible assets in the accompanying
Consolidated Statements of Operations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font size=
"1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The estimated remaining
amortization expense as of June&amp;#160;27, 2009 for each of the five
succeeding fiscal years is as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#160;&lt;/p&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" width="84%"
align="center"&gt;&lt;!-- 5 First_Row * DO NOT REMOVE OR EDIT --&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="89%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Remainder of Fiscal 2009&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;52,078&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Fiscal 2010&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;228,418&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Fiscal 2011&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;232,747&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Fiscal 2012&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;234,100&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Fiscal 2013&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;224,418&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- 6 Last_Row * DO NOT REMOVE OR EDIT --&gt;&lt;/tbody&gt;
&lt;/table&gt;
&lt;/div&gt;

</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
  <us-gaap:GoodwillImpairmentLoss contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">2340023000</us-gaap:GoodwillImpairmentLoss>
  <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
  <us-gaap:ImpairmentOfInvestments contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">2243000</us-gaap:ImpairmentOfInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">-2148928000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 0px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font size="2"
face="Times New Roman"&gt;&lt;b&gt;(14) Income Taxes&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The Company&amp;#8217;s effective
tax rates for the three and nine months ended June&amp;#160;27, 2009
were 32.4% and (2.9)%, respectively. The Company&amp;#8217;s effective
tax rates for the three and nine months ended June&amp;#160;28, 2008
were 35.3% and (42.1)%, respectively. The Company&amp;#8217;s effective
tax rate in the current three month period is lower that the
statutory rate primarily due to a $2.3 million benefit related to a
clarification in Massachusetts tax law on apportionment for
affiliates of manufacturing companies. The effective tax rate for
the current nine month period was significantly impacted by the
goodwill impairment charge recorded in the second quarter of fiscal
2009, substantially all of which is not deductible for tax
purposes. The effective tax rate for the nine months ended
June&amp;#160;28, 2008 was significantly impacted by the acquired
in-process research and development charge related to the Cytyc
merger, which is not deductible for tax purposes. As of
June&amp;#160;27, 2009, the Company has recorded a net deferred tax
liability of approximately $862,000. This liability is net of
approximately $56,000 of certain deferred tax assets.
Management&amp;#8217;s conclusion that such assets will be recovered is
based upon its expectation that the Company&amp;#8217;s future earnings
will provide sufficient taxable income. The realization of the
Company&amp;#8217;s deferred tax assets cannot be assured, and to the
extent that the Company fails to generate sufficient future taxable
income, some or all of the Company&amp;#8217;s deferred tax assets will
not be realized.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The Company had gross
unrecognized tax benefits, including interest, of approximately
$22,800 as of June&amp;#160;27, 2009. Of this amount, $8,100 represents
the amount of unrecognized tax benefits as of June&amp;#160;27, 2009
that, if recognized, would result in a reduction of the
Company&amp;#8217;s effective tax rate. Upon the adoption of SFAS
No.&amp;#160;141(R) changes in unrecognized tax benefits following an
acquisition generally will affect income tax expense, including any
changes associated with acquisitions that occurred prior to the
effective date of SFAS 141(R). In the next twelve months it is
reasonably possible that the Company will reduce the balance of its
unrecognized tax benefits by $2,274 due to the expiration of
statute of limitations and settlements with taxing authorities, of
which $1,481 will reduce the Company&amp;#8217;s effective tax
rate.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The Company&amp;#8217;s policy is
to recognize accrued interest and penalties related to unrecognized
tax benefits as part of income tax expense. As of June&amp;#160;27,
2009, accrued interest was approximately $1,100, net of federal
benefit. As of June&amp;#160;27, 2009, no penalties have been
accrued.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The Company and its
subsidiaries are subject to U.S. federal income tax, as well as
income tax of multiple state income and foreign jurisdictions. The
current tax returns are open for audit through fiscal
2013.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The Company currently has a
tax holiday in Costa Rica that is scheduled to expire in 2015. This
tax holiday does not materially reduce the Company&amp;#8217;s income
tax provision for fiscal 2009.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">62249000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">-9634000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">-39150000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">-26095000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">14396000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">15878000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">1048000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">-2718000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:InterestExpense contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">53057000</us-gaap:InterestExpense>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">999000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">-196362000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">-51310000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">395624000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">-2211177000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">-2092385000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" align="center"&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font face=
"Times New Roman" size="2"&gt;&lt;b&gt;(1) Basis of
Presentation&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;The consolidated financial
statements of Hologic, Inc. (the &amp;#8220;Company&amp;#8221;) presented
herein have been prepared pursuant to the rules of the Securities
and Exchange Commission for quarterly reports on Form 10-Q and do
not include all of the information and disclosures required by U.S.
generally accepted accounting principles. These financial
statements should be read in conjunction with the consolidated
financial statements and notes thereto for the year ended
September&amp;#160;27, 2008, included in the Company&amp;#8217;s
Form&amp;#160;10-K as filed with the Securities and Exchange Commission
on November&amp;#160;26, 2008. In the opinion of management, the
financial statements and notes contain all adjustments (consisting
of normal recurring accruals) considered necessary for a fair
presentation of the Company&amp;#8217;s financial position, results of
operations and cash flows for the periods presented.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;The preparation of financial
statements in conformity with U.S. generally accepted accounting
principles requires management to make significant estimates and
assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at
the date of the financial statements and the reported amounts of
revenues and expenses during the reporting periods. Actual results
could differ from management&amp;#8217;s estimates if past experience
or other assumptions do not turn out to be substantially accurate.
Operating results for the three and nine months ended June&amp;#160;27,
2009 are not necessarily indicative of the results to be expected
for any other interim period or the entire fiscal year ending
September&amp;#160;26, 2009.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;Based on a combination of
factors, including the deteriorating macro-economic environment,
declines in the stock market and the decline of the Company&amp;#8217;s
market capitalization significantly below the book value of its net
assets, the Company concluded that potential goodwill impairment
indicators existed as of December&amp;#160;27, 2008. During the second
quarter of fiscal 2009, the Company completed its interim goodwill
impairment analysis and recorded a goodwill impairment charge of
$2,340,023 for the three months ended March&amp;#160;28, 2009. Please
refer to Note 17 for further discussion.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;On May&amp;#160;28, 2009, the
FASB issued Statement of Financial Accounting Standards
(&amp;#8220;SFAS&amp;#8221;) No.&amp;#160;165, &lt;i&gt;Subsequent Events&lt;/i&gt;
(&amp;#8220;SFAS 165&amp;#8221;). This Statement provides authoritative
accounting literature on subsequent events that was previously only
addressed in the auditing literature and is largely consistent with
the current guidance in the auditing literature. The Company
considers events or transactions that occur after the balance sheet
date but prior to the issuance of the financial statements to
provide additional evidence relative to certain estimates or to
identify matters that require additional disclosure. Subsequent
events have been evaluated through August 6, 2009, the date these
financial statements are considered issued, and the financial
statements reflect those material items that arose after the
balance sheet date but prior to this date that would be considered
recognized subsequent events. There were no material recognized
subsequent events recorded in the June&amp;#160;27, 2009 financial
statements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;During the fourth quarter of
fiscal 2008, the Company determined that certain amounts previously
classified as a component of &amp;#8220;Cost of service and other
revenues&amp;#8221; should be reclassified to &amp;#8220;Cost of product
sales&amp;#8221;. The Company determined that the reclassification was
not material to its consolidated financial statements and corrected
the classification in the fourth quarter of fiscal 2008. These
amounts totaled $13,293 and $34,949 for the three and nine months
ended June&amp;#160;28, 2008, respectively, and have been reclassified
to &amp;#8220;Cost of product sales&amp;#8221; to conform with the current
period presentation. Additionally, royalty expense previously
recorded within &amp;#8220;Cost of service and other revenues&amp;#8221;
totaling $398 and $1,198 for the three and nine months ended
June&amp;#160;28, 2008, respectively, has been reclassified to
&amp;#8220;Cost of product sales&amp;#8221; to conform with the current
period presentation. The Company also reclassified other receivable
amounts of $5,902 from &amp;#8220;Accounts receivable&amp;#8221; to
&amp;#8220;Prepaid expenses and other current assets&amp;#8221; at
September&amp;#160;27, 2008 to conform to the current period
presentation.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;During fiscal 2009, the
Company reclassified certain amounts in the Consolidated Statement
of Cash Flows for the nine months ended June&amp;#160;28, 2008 to
conform to the current period presentation. As a result, net cash
provided by operations decreased to $239,061 from $274,601
primarily due to reclassifying $39,659 of excess tax benefits from
the exercise of stock options as a cash outflow in operating
activities with an offsetting cash inflow in the financing section
and reclassifying $851 of payments to tax authorities for tax
withholdings on the vesting of restricted stock units issued to
employees as a cash outflow in the financing section resulting in
cash flows provided by financing activities increasing to
$1,855,512 from $1,816,704. The Company also reclassified certain
other assets and other liabilities to cash flows provided by
operating activities from cash used in investing activities, which
increased to $2,073,408 from $2,070,140, to conform to the current
period presentation. In addition, there were insignificant
reclassifications of certain amounts within the line items of the
investing activities section.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;During the third quarter of
fiscal 2009, the Company determined that certain amounts previously
classified as a component of &amp;#8220;Selling and marketing&amp;#8221;
should be reclassified to &amp;#8220;Cost of product sales&amp;#8221;. This
reclassification, which aggregated $1,393 for the first and second
quarters of fiscal 2009, is not material to the Company&amp;#8217;s
consolidated financial statements and is reflected in the
Consolidated Statement of Operations for the nine months ended
June&amp;#160;27, 2009.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:OtherAdjustmentsForNoncashItemsIncludedInIncomeLossFromContinuingOperations contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">-427000</us-gaap:OtherAdjustmentsForNoncashItemsIncludedInIncomeLossFromContinuingOperations>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">-4485000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherPaymentsToAcquireBusinesses contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">229000</us-gaap:OtherPaymentsToAcquireBusinesses>
  <us-gaap:PaymentsOfFinancingCosts contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">350000</us-gaap:PaymentsOfFinancingCosts>
  <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
  <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">7414000</us-gaap:PaymentsToAcquireIntangibleAssets>
  <us-gaap:PaymentsToAcquireLifeInsurancePolicies contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">5322000</us-gaap:PaymentsToAcquireLifeInsurancePolicies>
  <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">0</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:PaymentsToAcquireOtherInvestments contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">400000</us-gaap:PaymentsToAcquireOtherInvestments>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">24809000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 0px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font size="2"
face="Times New Roman"&gt;&lt;b&gt;(8) Pension and Other Employee
Benefits&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;In conjunction with its
acquisition of AEG, the Company assumed certain defined benefit
pension plans covering the employees of the AEG German subsidiary
(the &amp;#8220;Pension Benefits&amp;#8221;). As of September&amp;#160;29, 2007
the Company adopted SFAS No.&amp;#160;158, &lt;i&gt;Employers&amp;#8217;
Accounting for Defined Benefit Pension and Other Postretirement
Plans, an amendment of FASB Statements No.&amp;#160;87, 88, 106 and
132(R)&lt;/i&gt; (&amp;#8220;SFAS 158&amp;#8221;), using a prospective approach.
The adoption of SFAS 158 did not impact the Company&amp;#8217;s
compliance with its debt covenants under its credit agreements,
cash position or results of operations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;As of June&amp;#160;27, 2009 and
September&amp;#160;27, 2008, the Company has recorded a pension
liability of $7,039 and $7,323, respectively, primarily as a
component of long-term liabilities, in the accompanying
consolidated financial statements. As of June&amp;#160;27, 2009 and
September&amp;#160;27, 2008, the pension plans held no assets. Under
German law, there are no rules governing investment or statutory
supervision of the pension plan. As such, there is no minimum
funding requirement imposed on employers. Pension benefits are
safeguarded by the Pension Guaranty Fund, a form of compulsory
reinsurance that guarantees an employee will receive vested pension
benefits in the event of insolvency. The Company&amp;#8217;s net
periodic benefit cost and components thereof were not material
during the nine months ended June&amp;#160;27, 2009 and June&amp;#160;28,
2008.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;

</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">0</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromLinesOfCredit contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">0</us-gaap:ProceedsFromLinesOfCredit>
  <us-gaap:ProceedsFromNotesPayable contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">0</us-gaap:ProceedsFromNotesPayable>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">0</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
  <us-gaap:ProceedsFromSaleOfIntangibleAssets contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">1500000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
  <us-gaap:ProductWarrantyDisclosureTextBlock contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font size="2"
face="Times New Roman"&gt;&lt;b&gt;(15) Product Warranties&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The Company generally offers
a one-year warranty for its products. The Company provides for the
estimated cost of product warranties at the time product revenue is
recognized with the exception of the Company&amp;#8217;s R2 CAD and
Dimensions digital mammography products for which the Company
defers the vendor-specific objective evidence of fair value of the
post contract support to be provided during the warranty period.
Factors that affect the Company&amp;#8217;s warranty reserves include
the number of units sold, historical and anticipated rates of
warranty repairs and the cost per repair. The Company periodically
assesses the adequacy of the warranty reserve and adjusts the
amount as necessary.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;Product warranty activity for
the nine months ended June&amp;#160;27, 2009 and June&amp;#160;28, 2008 is
as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#160;&lt;/p&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" width="100%"
align="center"&gt;&lt;!-- 5 First_Row * DO NOT REMOVE OR EDIT --&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="55%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;Balance&amp;#160;at&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;beginning&amp;#160;of&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font size="1" face="Times New Roman"&gt;&lt;b&gt;period&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;Accruals&amp;#160;for&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;warranties&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;provided&amp;#160;during&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;the&amp;#160;period&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;Accruals&amp;#160;for&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;warranties&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;acquired&amp;#160;during&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;the&amp;#160;period&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" nowrap="nowrap" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;Write-offs/&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font size="1" face="Times New Roman"&gt;&lt;b&gt;payments&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;Balance&amp;#160;at&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;end&amp;#160;of&amp;#160;period&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Nine Months Ended:&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;June&amp;#160;27, 2009&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;9,109&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;3,265&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;(6,256&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;6,118&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;June&amp;#160;28, 2008&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;12,087&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;7,369&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;591&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;(9,135&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;10,912&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- 6 Last_Row * DO NOT REMOVE OR EDIT --&gt;&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font size=
"1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;

</us-gaap:ProductWarrantyDisclosureTextBlock>
  <us-gaap:RepaymentsOfAssumedDebt contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">298000</us-gaap:RepaymentsOfAssumedDebt>
  <us-gaap:RepaymentsOfLinesOfCredit contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">195307000</us-gaap:RepaymentsOfLinesOfCredit>
  <us-gaap:RepaymentsOfNotesPayable contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">2168000</us-gaap:RepaymentsOfNotesPayable>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">71628000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentInProcess contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">0</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:RestructuringCharges contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">0</us-gaap:RestructuringCharges>
  <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0">&lt;div&gt;
&lt;h5 align="left"&gt;&lt;/h5&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&lt;b&gt;(16) Restructuring Accrual&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;As a result of the Cytyc
merger and the acquisition of Third Wave in the first and fourth
quarters of fiscal 2008, respectively, the Company recorded
liabilities related to restructuring plans, approved by the
previous management of those companies and designed to reduce
future operating expenses and recorded liabilities, of $4,658 and
$7,509, respectively. In connection with the Cytyc merger, the
Company assumed an arrangement in which the Company is sub-leasing
all of its Mountain View facility to a third party for a term of
approximately five years, a period of time equivalent to the
remainder of the Company&amp;#8217;s lease of this facility. The
sub-lease commenced on July&amp;#160;1, 2007. The Company has not
incurred any additional restructuring costs related to these plans,
and it is anticipated that these costs will be paid in full during
fiscal 2009.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;Additionally, during fiscal
2008 the Company recorded a liability related to the Cytyc merger
in accordance with EITF 95-3, primarily related to the termination
of certain employees as well as minimum inventory purchase
commitments and other contractual obligations for which business
activities have been discontinued.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;Changes in the restructuring
accrual for the nine months ended June&amp;#160;27, 2009 were as
follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#160;&lt;/p&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" width="92%"
align="center"&gt;&lt;!-- 5 First_Row * DO NOT REMOVE OR EDIT --&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="82%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;Other&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;Termination&lt;br /&gt;
Benefits&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Beginning balance, September 27, 2008&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;882&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;1,309&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Adjustments&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;(720&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;(461&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Payments&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;(128&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;(742&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Ending balance, June 27, 2009&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;34&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;106&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- 6 Last_Row * DO NOT REMOVE OR EDIT --&gt;&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;On May&amp;#160;20, 2008, the
Company entered into a Separation and Release Agreement (the
&amp;#8220;Separation Agreement&amp;#8221;) with Patrick J. Sullivan,
former Chairman of the Board of Directors of the Company. The
Separation Agreement required the Company to pay Mr.&amp;#160;Sullivan
a total of $4,442 and continue to pay Mr.&amp;#160;Sullivan&amp;#8217;s
premiums for COBRA continuation coverage under the Company&amp;#8217;s
group medical plan for eighteen months following the effective date
of the separation. In addition, the Separation Agreement provided
that Mr.&amp;#160;Sullivan&amp;#8217;s 45,710 restricted stock units
granted pursuant to a Restricted Stock Unit Agreement dated
October&amp;#160;22, 2007 would become fully vested, and
Mr.&amp;#160;Sullivan&amp;#8217;s options to purchase the Company&amp;#8217;s
common stock, all of which were fully vested, would be extended so
as to remain exercisable until August&amp;#160;31, 2009. The
acceleration of the restricted stock units and modification of
options resulted in a stock-based compensation charge of $1,941.
The Company recorded the lump sum payment and stock-based
compensation charge totaling $6,383 as a restructuring charge in
the accompanying Consolidated Statement of Operations during the
three months ended June&amp;#160;28, 2008.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;

</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
  <us-gaap:Revenues contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">1234367000</us-gaap:Revenues>
  <us-gaap:SalesRevenueGoodsNet contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">1081409000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueServicesNet contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">152958000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font size="2"
face="Times New Roman"&gt;&lt;b&gt;(13) Litigation and Other
Matters&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;On October&amp;#160;5, 2007,
Ethicon Endo-Surgery, Inc., a Johnson&amp;#160;&amp;amp; Johnson operating
company, filed a complaint against the Company and its wholly-owned
subsidiary Suros in the United States District Court for the
Southern District of Ohio, Western Division. The complaint alleges
that certain of the ATEC biopsy systems manufactured and sold by
Suros infringe four Ethicon patents. An amended complaint filed
January&amp;#160;11, 2008 additionally asserts claims of unfair
competition. The complaint seeks to enjoin Hologic and Suros from
conducting acts of unfair competition and infringing the patents as
well as the recovery of unspecified damages and costs. A Markman
hearing was held on January&amp;#160;8, 2009, and the Court issued its
ruling on April&amp;#160;3, 2009. A court ordered settlement conference
is scheduled for August&amp;#160;11, 2009. Given the stage of the
litigation, the Company is unable to reasonably estimate the
ultimate outcome of this case.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;On January&amp;#160;9, 2008,
Tissue Extraction Devices, LLC filed a complaint against the
Company and Suros in the United States District Court for the
Northern District of Illinois, alleging infringement of US Patent
No.&amp;#160;7,316,726 by certain of the ATEC biopsy systems
manufactured and sold by Suros. The complaint seeks to enjoin the
Company and Suros from infringing the patents as well as the
recovery of damages and costs resulting from the alleged
infringement. On May&amp;#160;20, 2008, the judge in Illinois granted
the Company&amp;#8217;s motion to transfer the case to the United
States District Court for the Southern District of Indiana. On
April&amp;#160;14, 2009, the parties entered into a confidential
settlement agreement calling for an immaterial payment by the
Company in exchange for a fully paid up license to the patent in
suit and related family member patent applications. The suit was
dismissed with prejudice by the Court on April&amp;#160;24,
2009.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;In October 2005, Third Wave,
which the Company acquired by way of merger on July&amp;#160;24, 2008,
filed a declaratory judgment suit in the United States District
Court for the Western District of Wisconsin against Digene
Corporation seeking a ruling that its HPV ASRs do not infringe any
valid claims of Digene&amp;#8217;s human papillomavirus related
patents. In January 2006, Third Wave reached an agreement with
Digene to dismiss the suit without prejudice. Third Wave also
agreed that neither party would file a suit against the other
relating to the human papillomavirus patents for one year. After
this period expired, on January&amp;#160;11, 2007, Digene Corporation
filed suit against Third Wave in the United States Court for the
Western District of Wisconsin. The complaint alleged patent
infringement of unidentified claims of a single patent related to
HPV type 52 by Third Wave&amp;#8217;s HPV ASR product. Third Wave filed
its response to Digene&amp;#8217;s complaint on February&amp;#160;28, 2007,
which, in addition to denying the alleged infringement, also
asserted that certain Digene sales practices violate certain
antitrust laws. After conducting a hearing on June&amp;#160;22, 2007,
the court released its claim construction order on July&amp;#160;23,
2007 adopting all of Third Wave&amp;#8217;s proposed construction. On
July&amp;#160;31, 2007, Digene filed a motion to reconsider the
court&amp;#8217;s claim construction. On September&amp;#160;26, 2007, the
court issued an order denying Digene&amp;#8217;s motion for
reconsideration in its entirety and upheld the earlier claim
construction ruling. In response, in a filing to the court, Digene
stated that it &amp;#8220;believes it will not be able to sustain its
claim of infringement.&amp;#8221; On October&amp;#160;19, 2007 Digene filed
a motion for summary judgment on Third Wave&amp;#8217;s antitrust
counterclaims. On November&amp;#160;23, 2007, the court issued an order
dismissing Digene&amp;#8217;s patent infringement claims. On
January&amp;#160;11, 2008, the court issued an order granting
Digene&amp;#8217;s motion for summary judgment on Third Wave&amp;#8217;s
antitrust counterclaims. On February&amp;#160;29, 2008, both Third Wave
and Digene filed notices of appeal to the Court of Appeals for the
Federal Circuit. Oral arguments for the appeal were conducted on
February&amp;#160;2, 2009. On April&amp;#160;1, 2009, the Court of Appeals
for the Federal Circuit issued its ruling affirming the judgment of
the United States District Court for the Western District of
Wisconsin dismissing Digene&amp;#8217;s patent infringement claim
against Third Wave and Third Wave&amp;#8217;s antitrust counterclaim
against Digene.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;On May&amp;#160;22, 2009,
Conceptus, Inc. filed suit in the United States District Court for
the Northern District of California seeking a declaration by the
Court that Hologic&amp;#8217;s planned importation, use, sale or offer
to sell of its forthcoming Adiana Permanent Contraception system,
would infringe five Conceptus patents. On July&amp;#160;9, 2009,
Conceptus filed an amended complaint alleging infringement of the
same five patents by the Adiana Permanent Contraception system. The
complaint seeks preliminary and permanent injunctive relief and
unspecified monetary damages. In addition to the amended complaint,
Conceptus also filed a motion for preliminary injunction seeking to
preliminarily enjoin sales of the Adiana system based on alleged
infringement of certain claims of three of the five patents. Based
on the early stage of this litigation, the Company is unable to
reasonably estimate the ultimate outcome of this case.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font size=
"1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The Company is a party to
various other legal proceedings arising out of the ordinary course
of its business. The Company believes that there are no other
proceedings pending against it which, if determined adversely,
would have a material adverse effect on its financial condition or
results of operations.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;

</us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock>
  <us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font size="2"
face="Times New Roman"&gt;&lt;b&gt;(19) Recent Accounting
Pronouncements&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;In April&amp;#160;2009, the FASB
issued FSP FAS 115-2 and FAS 124-2, &lt;i&gt;Recognition and Presentation
of Other-Than-Temporary Impairment&lt;/i&gt; (FSP 115-2/124-2). FSP
115-2/124-2 amends the requirements for the recognition and
measurement of other-than-temporary impairments for debt securities
by modifying the pre-existing &amp;#8220;intent and ability&amp;#8221;
indicator. Under FSP 115-2/124-2, an other-than-temporary
impairment is triggered when there is an intent to sell the
security, it is more likely than not that the security will be
required to be sold before recovery, or the security is not
expected to recover the entire amortized cost basis of the
security. Additionally, FSP 115-2/124-2 changes the presentation of
an other-than-temporary impairment in the income statement for
those impairments involving credit losses. The credit loss
component will be recognized in earnings and the remainder of the
impairment will be recorded in other comprehensive income. FSP
115-2/124-2 is effective for the Company beginning with the third
quarter of fiscal 2009. The adoption of FSP 115-2/124-2 did not
have a significant impact on the Company&amp;#8217;s consolidated
financial statements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;In December 2007, the FASB
issued SFAS No.&amp;#160;141 (Revised 2007), &lt;i&gt;Business
Combinations&lt;/i&gt; (&amp;#8220;SFAS 141(R)&amp;#8221;). This Statement
retains the fundamental requirements in SFAS 141 that the
acquisition method of accounting (which SFAS 141 called the
purchase method) be used for all business combinations and for an
acquirer to be identified for each business combination. SFAS
141(R) requires an acquirer to recognize the assets acquired, the
liabilities assumed, and any noncontrolling interest in the
acquiree at the acquisition date, measured at their fair values as
of that date, with limited exceptions specified in the Statement.
SFAS 141(R) replaces SFAS 141&amp;#8217;s cost-allocation process,
which required the cost of an acquisition to be allocated to the
individual assets acquired and liabilities assumed based on their
estimated fair values. The Statement retains the guidance in SFAS
141 for identifying and recognizing intangible assets separately
from goodwill. SFAS 141(R) will now require acquisition costs to be
expensed as incurred, and changes in deferred tax asset valuation
allowances and income tax uncertainties after the acquisition date
generally to affect income tax expense. SFAS 141(R) applies
prospectively to business combinations for which the acquisition
date is on or after the beginning of the first annual reporting
period beginning on or after December&amp;#160;15, 2008, which is the
Company&amp;#8217;s 2010 fiscal year. Early adoption is prohibited. The
Company is currently evaluating the impact that the adoption of
SFAS&amp;#160;141(R) will have on its consolidated financial
statements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;In December 2007, the FASB
issued SFAS No.&amp;#160;160, &lt;i&gt;Noncontrolling Interests in
Consolidated Financial Statements&amp;#8212;An amendment of ARB
No.&amp;#160;51&lt;/i&gt; (&amp;#8220;SFAS 160&amp;#8221;). SFAS 160 amends
Accounting Research Bulletin (&amp;#8220;ARB&amp;#8221;) No.&amp;#160;51 to
establish accounting and reporting standards for the noncontrolling
interest in a subsidiary and for the deconsolidation of a
subsidiary. It clarifies that a noncontrolling interest in a
subsidiary is an ownership interest in the consolidated entity that
should be reported as equity in the consolidated financial
statements. The amount of net income attributable to the
noncontrolling interest will be included in consolidated&lt;/font&gt;
&lt;font size="2" face="Times New Roman"&gt;net income on the face of the
income statement. SFAS 160 clarifies that changes in a
parent&amp;#8217;s ownership interest in a subsidiary that do not
result in deconsolidation are equity transactions if the parent
retains its controlling financial interest. In addition, this
Statement requires that a parent recognize a gain or loss in net
income when a subsidiary is deconsolidated. SFAS 160 is effective
for fiscal years, and interim periods within those fiscal years,
beginning on or after December&amp;#160;15, 2008, which is the
Company&amp;#8217;s 2010 fiscal year. Early adoption is prohibited. We
do not expect the adoption of this standard to have an impact on
our financial position or results of operations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;In April 2008, the FASB
issued FASB Staff Position (&amp;#8220;FSP&amp;#8221;) No.&amp;#160;142-3,
&lt;i&gt;Determination of the Useful Life of Intangible Assets&lt;/i&gt;, which
amends the factors that must be considered in developing renewal or
extension assumptions used to determine the useful life over which
to amortize the cost of a recognized intangible asset under SFAS
142. The objective of this FSP is to improve the consistency
between the useful life of a recognized intangible asset under SFAS
142 and the period of expected cash flows used to measure the fair
value of the asset under SFAS 141(R). The FSP is effective for
financial statements for fiscal years beginning after
December&amp;#160;15, 2008, which will be the beginning of fiscal 2010
for the Company. The Company is currently evaluating the impact
that the adoption of this FSP will have on its consolidated
financial statements. Early adoption is prohibited.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;In May 2008, the FASB issued
FSP No. APB 14-1&lt;i&gt;, Accounting for Convertible Debt Instruments
That May Be Settled in Cash upon Conversion (Including Partial Cash
Settlement).&lt;/i&gt; This FSP applies to convertible debt instruments
that, by their stated terms, may be settled in cash (or other
assets) upon conversion, including partial cash settlement, unless
the embedded conversion option is required to be separately
accounted for as a derivative under SFAS&amp;#160;133. The liability
and equity components of convertible debt instruments within the
scope of this FSP must be separately accounted for in a manner that
will reflect the entity&amp;#8217;s nonconvertible debt borrowing rate
when interest cost is recognized in subsequent periods. The excess
of the principal amount of the debt over the amount ultimately
allocated to the liability component is required to be amortized to
interest expense using the interest method. This FSP is effective
for financial statements issued for fiscal years beginning after
December&amp;#160;15, 2008, and interim periods within those fiscal
years. As a result, the Company will adopt this standard at the
beginning of fiscal 2010. This FSP must be applied retrospectively
to all periods presented. The retrospective adoption of this FSP
will increase the Company&amp;#8217;s historical reported interest
expense from December&amp;#160;10, 2007 (issuance date of the
Convertible Notes &amp;#8211; See Note 6) forward.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The adoption of FSP APB 14-1
will have no impact on the Company&amp;#8217;s actual past or future
cash flows. However, upon adoption in fiscal 2010, the Company will
restate prior periods by reclassifying approximately $470,000 of
its Convertible Notes to additional paid-in capital, resulting in a
debt discount. It is estimated that the Company&amp;#8217;s non-cash
interest expense will increase by approximately $16,600 and $48,700
for the three and nine months ended June&amp;#160;27, 2009,
respectively, and approximately $15,300 and $32,700 for the three
and nine months ended June&amp;#160;28, 2008, respectively, resulting
in a restated diluted net income (loss) per share of approximately
$0.12 and $(8.74) for the three and nine months ended June&amp;#160;27,
2009, respectively, and a restated diluted net income (loss) per
share of approximately $0.20 and $(1.08) for the three and nine
months ended June&amp;#160;28, 2008, respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;In June 2008, the FASB
ratified the consensus reached on EITF Issue No.&amp;#160;07-5,
&lt;i&gt;Determining Whether an Instrument (or Embedded Feature) Is
Indexed to an Entity&amp;#8217;s Own Stock&lt;/i&gt; (&amp;#8220;EITF
07-5&amp;#8221;). EITF 07-5 clarifies the determination of whether an
instrument (or an embedded feature) is indexed to an entity&amp;#8217;s
own stock, which would qualify as a scope exception under SFAS 133.
EITF 07-5 is effective for financial statements issued for fiscal
years beginning after December&amp;#160;15, 2008. Early adoption for an
existing instrument is not permitted. The Company has concluded
that upon the adoption of this standard, the embedded derivative
option in the Company&amp;#8217;s Convertible Notes (See Note 6) will
continue to be considered indexed to the Company&amp;#8217;s own stock.
As a result, the adoption of EITF 07-05 is not expected to have a
material impact on the Company&amp;#8217;s financial condition or
results of operations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;In April 2009, the FASB
issued FSP SFAS 107-1 and APB 28-1, &lt;i&gt;Interim Disclosures about
Fair Value of Financial Instruments&lt;/i&gt;, (&amp;#8220;FSP SFAS 107-1 and
APB 28-1&amp;#8221;). FSP SFAS 107-1 and APB 28-1 amend SFAS
No.&amp;#160;107, &lt;i&gt;Disclosures about Fair Value of Financial
Instruments&lt;/i&gt;, to require disclosures about fair value of
financial instruments in interim as well as in annual financial
statements. FSP SFAS 107-1 and APB 28-1 also amend APB Opinion No
28, Interim Financial Reporting, to require fair value disclosures
in all interim financial statements. FSP SFAS 107-1 and APB 28-1
are effective for the Company in its third quarter of fiscal 2009
and did not have a material impact on the Company&amp;#8217;s financial
position, results of operations or cash flows.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;In June 2009, the FASB issued
SFAS No.&amp;#160;168, &lt;i&gt;The FASB Accounting Standards Codification
and the Hierarchy of Generally Accepted Accounting Principles,&lt;/i&gt;
which establishes the FASB Accounting Standards Codification as the
single source of authoritative U.S. GAAP. The Codification will
supersede all existing non-SEC accounting and reporting standards.
As a result, upon adoption, all references to accounting literature
in our SEC filings will conform to the appropriate reference within
the Codification. The Company is required to adopt SFAS
No.&amp;#160;168 for the Company&amp;#8217;s fiscal fourth quarter ending
September&amp;#160;26, 2009. The Company does not expect the adoption
of this standard to have an impact on its financial position or
results of operations.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;

</us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
  <us-gaap:SegmentReportingDisclosureTextBlock contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font size="2"
face="Times New Roman"&gt;&lt;b&gt;(12) Business Segments and Geographic
Information&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The Company reports segment
information in accordance with SFAS No.&amp;#160;131, &lt;i&gt;Disclosures
about Segments of an Enterprise and Related Information&lt;/i&gt;
(&amp;#8220;SFAS 131&amp;#8221;). Operating segments are identified as
components of an enterprise about which separate, discrete
financial information is available for evaluation by the chief
operating decision maker, or decision-making group, in making
decisions about how to allocate resources and assess performance.
The Company&amp;#8217;s chief decision-maker, as defined under SFAS
131, is the chief operating officer. The Company reports its
business as four segments: Breast Health, Diagnostics, GYN Surgical
and Skeletal Health. The Diagnostics segment includes the results
of Third Wave Technologies, which was acquired in the fourth
quarter of fiscal 2008.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;Identifiable assets for the
four principal operating segments consist of inventories,
intangible assets, and property and equipment. The Company has
presented all other identifiable assets as corporate assets.
Intersegment sales and transfers are not significant. Segment
information for the three and nine months ended June&amp;#160;27, 2009
and June&amp;#160;28, 2008 is as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#160;&lt;/p&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" width="100%"
align="center"&gt;&lt;!-- 5 First_Row * DO NOT REMOVE OR EDIT --&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="68%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="5" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="5" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;Nine Months Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;June&amp;#160;27,&lt;br /&gt;
2009&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;June&amp;#160;28,&lt;br /&gt;
2008&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;June&amp;#160;27,&lt;br /&gt;
2009&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;June&amp;#160;28,&lt;br /&gt;
2008&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Total revenues&amp;#8211;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Breast Health&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;174,892&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;219,498&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;554,084&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;639,808&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Diagnostics&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;139,530&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;126,564&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;409,189&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;351,311&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;GYN Surgical&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;65,840&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;56,310&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;197,594&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;161,417&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- 6 Last_Row * DO NOT REMOVE OR EDIT --&gt;&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font size=
"1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" width="100%"
align="center"&gt;&lt;!-- 5 First_Row * DO NOT REMOVE OR EDIT --&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="65%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="5" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="6" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;Nine Months Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;June&amp;#160;27,&lt;br /&gt;
2009&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;June&amp;#160;28,&lt;br /&gt;
2008&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;June&amp;#160;27,&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font size="1" face="Times New Roman"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;June&amp;#160;28,&lt;br /&gt;
2008&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Skeletal Health&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;22,858&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;27,120&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;73,500&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;79,450&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;403,120&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;429,492&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;1,234,367&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;1,231,986&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td height="8"&gt;&lt;/td&gt;
&lt;td height="8" colspan="3"&gt;&lt;/td&gt;
&lt;td height="8" colspan="3"&gt;&lt;/td&gt;
&lt;td height="8" colspan="4"&gt;&lt;/td&gt;
&lt;td height="8" colspan="4"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Operating income (loss) &amp;#8211;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Breast Health&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;32,640&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;56,421&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;(152,262&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;157,375&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Diagnostics&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;27,303&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;35,824&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;(836,176&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;(9,336&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;GYN Surgical&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;15,968&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;12,220&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;(1,114,746&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;(259,680&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Skeletal Health&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;2,835&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;3,156&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;10,799&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;2,590&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;78,746&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;107,621&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;(2,092,385&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;(109,051&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td height="8"&gt;&lt;/td&gt;
&lt;td height="8" colspan="3"&gt;&lt;/td&gt;
&lt;td height="8" colspan="3"&gt;&lt;/td&gt;
&lt;td height="8" colspan="4"&gt;&lt;/td&gt;
&lt;td height="8" colspan="4"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Depreciation and amortization&amp;#8211;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Breast Health&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;14,608&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;9,923&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;36,868&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;29,669&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Diagnostics&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;39,295&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;25,474&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;117,933&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;70,340&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;GYN Surgical&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;13,985&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;8,141&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;42,315&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;22,506&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Skeletal Health&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;2,517&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;1,573&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;6,170&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;4,463&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;70,405&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;45,111&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;203,286&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;126,978&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td height="8"&gt;&lt;/td&gt;
&lt;td height="8" colspan="3"&gt;&lt;/td&gt;
&lt;td height="8" colspan="3"&gt;&lt;/td&gt;
&lt;td height="8" colspan="4"&gt;&lt;/td&gt;
&lt;td height="8" colspan="4"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Capital expenditures&amp;#8211;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Breast Health&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;3,398&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;4,656&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;9,540&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;14,090&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Diagnostics&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;2,554&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;2,896&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;5,493&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;7,916&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;GYN Surgical&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;1,064&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;3,725&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;4,517&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;12,765&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Skeletal Health&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;1,157&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;2,051&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;5,259&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;7,499&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;8,173&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;13,328&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;24,809&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;42,270&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- 6 Last_Row * DO NOT REMOVE OR EDIT --&gt;&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#160;&lt;/p&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" width="100%"
align="center"&gt;&lt;!-- 5 First_Row * DO NOT REMOVE OR EDIT --&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="80%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;June&amp;#160;27,&lt;br /&gt;
2009&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;September&amp;#160;27,&lt;br /&gt;
2008&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Identifiable assets&amp;#8211;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Breast Health&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;1,147,756&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;1,435,674&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Diagnostics&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;1,968,753&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;2,976,854&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;GYN Surgical&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;1,867,458&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;3,080,365&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Skeletal Health&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;33,202&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;25,151&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Corporate&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;701,076&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;616,588&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;5,718,245&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;8,134,632&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- 6 Last_Row * DO NOT REMOVE OR EDIT --&gt;&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;As a result of the
Company&amp;#8217;s interim impairment analysis of goodwill as of
December&amp;#160;27, 2008, the Company recorded a goodwill impairment
charge of $2,340,023 during the three months ended March&amp;#160;28,
2009 comprised of $1,165,804 for GYN Surgical, $908,349 for
Diagnostics, and $265,870 for Breast Health. See Note 17 for
additional information pertaining to the interim impairment
analysis of the Company&amp;#8217;s goodwill.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;There were no customers with
balances greater than 10% of accounts receivable as of
June&amp;#160;27, 2009 or September&amp;#160;27, 2008, nor any customer
that represented greater than 10% of product revenues during the
three and nine months ended June&amp;#160;27, 2009 and June&amp;#160;28,
2008.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;Product export sales from the
U.S. to unaffiliated customers, primarily in Europe, Asia and Latin
America, during the three and nine months ended June&amp;#160;27, 2009
totaled $68,082 and $223,256, respectively, and for the three and
nine months ended June&amp;#160;28, 2008 totaled $71,101 and $218,840,
respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;Products sold by the Company
internationally are manufactured at domestic and international
manufacturing locations such as Costa Rica, where much of the GYN
Surgical products are currently being manufactured.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font size=
"1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;Transfers between the Company
and its subsidiaries are generally recorded at amounts similar to
the prices paid by unaffiliated foreign dealers. All intercompany
profit is eliminated in consolidation. There were no intersegment
revenues during the three and nine months ended June&amp;#160;27, 2009
and June 28, 2008.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;Export product sales as a
percentage of total product sales were as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#160;&lt;/p&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" width="100%"
align="center"&gt;&lt;!-- 5 First_Row * DO NOT REMOVE OR EDIT --&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="76%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="4" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;Three&amp;#160;Months&amp;#160;Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="4" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;Nine&amp;#160;Months&amp;#160;Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;June&amp;#160;27,&lt;br /&gt;
2009&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;June&amp;#160;28,&lt;br /&gt;
2008&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;June&amp;#160;27,&lt;br /&gt;
2009&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;June&amp;#160;28,&lt;br /&gt;
2008&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Europe&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;11&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;11&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;12&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;12&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Asia&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;4&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;4&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;4&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;4&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;All others&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;4&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;3&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;5&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;4&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;19&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;18&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;21&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;20&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
&lt;/div&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
  <us-gaap:SellingAndMarketingExpense contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">182402000</us-gaap:SellingAndMarketingExpense>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">24353000</us-gaap:ShareBasedCompensation>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="Shares" decimals="-3">256381000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="Shares" decimals="-3">256381000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <holx:DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font size="2"
face="Times New Roman"&gt;&lt;b&gt;(5) Other Balance Sheet
Information&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;Components of selected
captions in the Consolidated Balance Sheets at June&amp;#160;27, 2009
and September&amp;#160;27, 2008 consisted of:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#160;&lt;/p&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" width="100%"
align="center"&gt;&lt;!-- 5 First_Row * DO NOT REMOVE OR EDIT --&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="82%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;June&amp;#160;27,&lt;br /&gt;
2009&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;September&amp;#160;27,&lt;br /&gt;
2008&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&lt;b&gt;Inventories&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Raw material and work-in-process&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;118,229&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;106,291&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Finished goods&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;65,172&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;68,376&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;183,401&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;174,667&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- 6 Last_Row * DO NOT REMOVE OR EDIT --&gt;&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font size="2"
face="Times New Roman"&gt;Inventories are stated at the lower of cost
(first-in, first-out) or market.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#160;&lt;/p&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" width="100%"
align="center"&gt;&lt;!-- 5 First_Row * DO NOT REMOVE OR EDIT --&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="82%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;June 27,&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font size="1" face="Times New Roman"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;September&amp;#160;27,&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font size="1" face="Times New Roman"&gt;&lt;b&gt;2008&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&lt;b&gt;Property and Equipment, net&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Equipment and software&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;190,464&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;172,790&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Customer usage equipment&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;119,815&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;100,315&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Building and improvements&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;56,652&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;55,743&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Leasehold improvements&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;39,845&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;38,620&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Furniture and fixtures&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;11,438&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;11,083&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Land&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;8,932&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;8,978&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;427,146&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;387,529&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Less &amp;#8211; accumulated depreciation and
amortization&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;(149,506&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;(103,554&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;277,640&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;283,975&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- 6 Last_Row * DO NOT REMOVE OR EDIT --&gt;&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font size=
"1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&lt;b&gt;Restricted Cash&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;Restricted cash is currently
primarily comprised of various deposits for operating leases and
duty taxes. The Company paid $2,520 of the restricted cash balance
to certain former executives related to deferred compensation
during the three months ended June&amp;#160;27, 2009.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;

</holx:DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock>
  <holx:PaymentForTaxWithholdingRelatedToVestedAndReleasedRestrictedStockUnits contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">878000</holx:PaymentForTaxWithholdingRelatedToVestedAndReleasedRestrictedStockUnits>
  <holx:EarningsPerShareTextBlock contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font size="2"
face="Times New Roman"&gt;&lt;b&gt;(9) Net Income (Loss) Per
Share&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;Basic net income (loss) per
share is computed by dividing net income (loss) by the weighted
average number of common shares outstanding. Diluted net income
(loss) per share is computed by dividing net income (loss) by the
weighted average number of common shares outstanding plus the
dilutive effect of potential common shares from outstanding stock
options, restricted stock units and convertible debt determined by
applying the treasury stock method. In accordance with SFAS
No.&amp;#160;123 (revised 2004), &lt;i&gt;Share-Based Payment&lt;/i&gt;, the
assumed proceeds under the treasury stock method include the
average unrecognized compensation expense of stock options that are
in-the-money and restricted stock units.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;The Company applies the
provisions of EITF No.&amp;#160;04-8, &lt;i&gt;The Effect of Contingently
Convertible Instruments on Diluted Earnings per Share (&amp;#8220;EITF
04-8&amp;#8221;),&lt;/i&gt; to determine diluted weighted average shares
outstanding as it relates to its outstanding Convertible Notes, and
due to the type of debt instrument issued, the dilutive impact of
the Company&amp;#8217;s Convertible Notes is based on the difference
between the Company&amp;#8217;s current stock price and the conversion
price of the Convertible Notes, provided there is a premium. Under
EITF 04-8, there is no dilution from the accreted principal of the
Convertible Notes. Accordingly, the Company uses the treasury stock
method to determine dilutive weighted average shares related to its
Convertible Notes and not the if-converted method.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font size=
"1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;A reconciliation of basic and
diluted share amounts are as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#160;&lt;/p&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" width="100%"
align="center"&gt;&lt;!-- 5 First_Row * DO NOT REMOVE OR EDIT --&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="68%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="5" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="6" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;Nine Months Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;June&amp;#160;27,&lt;br /&gt;
2009&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;June&amp;#160;28,&lt;br /&gt;
2008&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;June&amp;#160;27,&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font size="1" face="Times New Roman"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom"
colspan="2" align="middle"&gt;&lt;font size="1" face=
"Times New Roman"&gt;&lt;b&gt;June&amp;#160;28,&lt;br /&gt;
2008&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Numerator:&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Net income (loss), as reported, for basic
earnings per share&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;41,000&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;61,379&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;(2,211,177&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;(241,244&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Interest expense on Cytyc convertible debt, net
of tax&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;1&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Net income (loss), as adjusted, for diluted
earnings per share&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;41,000&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;61,380&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;(2,211,177&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;(241,244&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Denominator:&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Basic weighted average common shares
outstanding&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;256,556&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;255,676&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;256,381&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;242,604&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Weighted average common stock equivalents from
assumed exercise of stock options and restricted stock
units&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;2,352&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;3,703&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Weighted average common stock equivalents from
assumed conversion of convertible notes&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;11&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Diluted weighted average common shares
outstanding&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;258,908&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;259,390&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;256,381&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;242,604&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Basic net income (loss) per common
share&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;0.16&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;0.24&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;(8.62&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;(0.99&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Diluted net income (loss) per common
share&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;0.16&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;0.24&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;(8.62&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;(0.99&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Weighted-average anti-dilutive shares related
to:&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Outstanding stock options&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;11,801&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;4,001&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;13,792&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;7,040&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font size="2" face=
"Times New Roman"&gt;Restricted stock units&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;53&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;1,079&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;1,812&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font size="2" face=
"Times New Roman"&gt;116&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font size="2" face=
"Times New Roman"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- 6 Last_Row * DO NOT REMOVE OR EDIT --&gt;&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="2" face="Times New Roman"&gt;Diluted weighted average
shares outstanding do not include any effect resulting from the
conversion of the Company&amp;#8217;s Convertible Notes issued in
December 2007 as their impact would be anti-dilutive for all
periods presented. In those reporting periods in which the Company
has reported net income, anti-dilutive shares comprise those common
stock equivalents that have either an exercise price above the
average stock price for the quarter or the common stock equivalents
related average unrecognized stock compensation expense is
sufficient to &amp;#8220;buy back&amp;#8221; the entire amount of shares.
In those reporting periods in which the Company has a net loss,
anti-dilutive shares comprise the impact of those number of shares
that would have been dilutive had the Company had net income plus
the number of common stock equivalents that would be anti-dilutive
had the company had net income.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;

</holx:EarningsPerShareTextBlock>
  <holx:CostOfGoodsSoldImpairmentOfIntangibleAssets contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">4065000</holx:CostOfGoodsSoldImpairmentOfIntangibleAssets>
  <holx:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">2111000</holx:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
  <holx:ImpairmentOfIntangibleAssetsFinitelived contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">4065000</holx:ImpairmentOfIntangibleAssetsFinitelived>
  <holx:FairValueWriteUpOfAcquiredInventory contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">1084000</holx:FairValueWriteUpOfAcquiredInventory>
  <holx:IncreaseDecreaseInPrepaidIncomeTaxes contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">-13872000</holx:IncreaseDecreaseInPrepaidIncomeTaxes>
  <holx:PaymentsToManufactureEquipmentUnderCustomerUsageAgreements contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">17354000</holx:PaymentsToManufactureEquipmentUnderCustomerUsageAgreements>
  <holx:ProceedsFromContingentSaleOfAssets contextRef="eol_PE45------0910-Q0003_STD_p9m_20090627_0" unitRef="USD" decimals="-3">0</holx:ProceedsFromContingentSaleOfAssets>
  <context id="eol_PE45------0910-Q0003_STD_p9m_20090627_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000859737</identifier>
    </entity>
    <period>
      <startDate>2008-09-28</startDate>
      <endDate>2009-06-27</endDate>
    </period>
  </context>
  <context id="eol_PE45------0910-Q0003_STD_p9m_20080628_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000859737</identifier>
    </entity>
    <period>
      <startDate>2007-09-30</startDate>
      <endDate>2008-06-28</endDate>
    </period>
  </context>
  <context id="eol_PE45------0910-Q0003_STD_p3m_20090627_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000859737</identifier>
    </entity>
    <period>
      <startDate>2009-03-29</startDate>
      <endDate>2009-06-27</endDate>
    </period>
  </context>
  <context id="eol_PE45------0910-Q0003_STD_p3m_20080628_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000859737</identifier>
    </entity>
    <period>
      <startDate>2008-03-30</startDate>
      <endDate>2008-06-28</endDate>
    </period>
  </context>
  <context id="eol_PE45------0910-Q0003_STD_Inst_20090627_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000859737</identifier>
    </entity>
    <period>
      <instant>2009-06-27</instant>
    </period>
  </context>
  <context id="eol_PE45------0910-Q0003_STD_Inst_20080628_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000859737</identifier>
    </entity>
    <period>
      <instant>2008-06-28</instant>
    </period>
  </context>
  <context id="eol_PE45------0910-Q0003_STD_Inst_20080328_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000859737</identifier>
    </entity>
    <period>
      <instant>2008-03-28</instant>
    </period>
  </context>
  <context id="eol_PE45------0910-Q0003_STD_Inst_20090803_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000859737</identifier>
    </entity>
    <period>
      <instant>2009-08-03</instant>
    </period>
  </context>
  <context id="eol_PE45------0910-Q0003_STD_Inst_20080927_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000859737</identifier>
    </entity>
    <period>
      <instant>2008-09-27</instant>
    </period>
  </context>
  <context id="eol_PE45------0910-Q0003_STD_Inst_20070929_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000859737</identifier>
    </entity>
    <period>
      <instant>2007-09-29</instant>
    </period>
  </context>
  <unit id="USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="USDperShareItemType">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Shares">
    <measure>shares</measure>
  </unit>
  <xbrll:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <xbrll:loc xlink:href="#fnid_453490_1_17" xlink:label="fnid_453490_1_17" xlink:type="locator"/>
    <xbrll:loc xlink:href="#fnid_453490_2_17" xlink:label="fnid_453490_2_17" xlink:type="locator"/>
    <xbrll:loc xlink:href="#fnid_453490_3_17" xlink:label="fnid_453490_3_17" xlink:type="locator"/>
    <xbrll:loc xlink:href="#fnid_453490_4_17" xlink:label="fnid_453490_4_17" xlink:type="locator"/>
    <xbrll:footnote xlink:label="footnote_453470" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Stock-based compensation included in costs and expenses during the three and nine months ended June 27, 2009 was $913 and $2,625 for cost of revenues, $747 and $3,095 for research and development, $1,228 and $4,005 for selling and marketing and $5,122 and $14,628 for general and administrative. Stock-based compensation included in costs and expenses during the three and nine months ended June 28, 2008 was $508 and $1,751 for cost of revenues, $553 and $1,782 for research and development, $907 and $2,402 for selling and marketing and $3,073 and $11,612 for general and administrative. The restructuring charge line item includes $1,941 for both the three and nine months ended June 28, 2008.</xbrll:footnote>
    <xbrll:footnoteArc xlink:from="fnid_453490_1_17" xlink:to="footnote_453470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="fnid_453490_2_17" xlink:to="footnote_453470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="fnid_453490_3_17" xlink:to="footnote_453470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="fnid_453490_4_17" xlink:to="footnote_453470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
  </xbrll:footnoteLink>
</xbrl>